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ABSTRACT 
HSIN-YI HUNG: DDB and Betulinic Acid-derivatives as Potent Chemosensitizing, Chemopreventive, 
and Anti-HIV Agents 
(Under the direction of Kenan Professor Kuo-Hsiung Lee) 
 
The overall goals of this research are to design and synthesize novel DDB and betulinic acid 
derivatives to evaluate their chemosensitizing, chemopreventive, and anti-HIV activities. Structure-
activity relationships (SAR) are established in order to discover novel chemical entities, and to 
explore the mechanism(s) of action.  
Dimethyl diphenyl bicarboxylate (DDB) and its analog, bicyclol, were reported to have 
chemosensitizing activity in several multidrug resistant cancer cell lines. In a continuing study, an 
easy modification was accomplished by reduction to 2,2-bismethylhydroxy DDB followed by 
esterification with various acids. This synthetic route was applied to develop a series of compounds 
and establish SAR. SAR studies on these compounds revealed that analogs with aromatic and bulky 
aliphatic side chains at the 2,2′-positions effectively and significantly sensitized MDR-1 over-
expressed cells to three anticancer drugs, paclitaxel (TAX), vincristine (VCR), and doxorubicin 
(DOX). DDB derivatives 83 and 90 were five to ten times more effective than verapamil (VRP) for 
TAX and VCR reversal ability. Analog 73 also showed five times greater chemosensitizing effect 
than VRP against DOX. The mechanism of action studies showed that DDB analogs elevate cellular 
concentration of DOX via inhibition of P-glycoprotein.  
Nineteen DDB analogs were evaluated in an in vitro short-term Epstein Barr virus early antigen 
(EBA-EA) activation assay.  Three of the most potent compounds (83, 85 and 106) were also tested 
for inhibitory effects on skin tumor promotion in an in vivo two-stage mouse-skin 
iv 
 
carcinogenesis test. Compound 106 with a prenyl ether had the most significant cancer preventive 
activity in vitro, and it also exhibited a remarkable inhibitory effect on skin tumor promotion in 
an in vivo two-stage mouse-skin carcinogenesis test. 
Importantly, active DDB analogs displayed no cytotoxicity either in chemoreversal or cancer 
prevention assays, suggesting that they are good leads for further development.  
In chapter 5, another natural product, betulinic acid, was studied since our group has focused on 
modification of this molecule for years. Most researches were on the modifications of positions 3, 19 
and 28. Modifications on ring A were largely under investigation. Therefore, thirteen new betulinic 
acid derivatives were designed, synthesized, and evaluated for anticancer, cancer prevention, or anti-
HIV activity. In the cytotoxic activity evaluation, compounds 120, 123, 126, and 129 exhibited GI50 < 
10 µM, and compound 120 with a 3-methyl ester and 4, 23-vinyl group was the most potent. SAR 
study showed that the 3-methyl ester and 4, 23-vinyl group are important for potency. A C-3 
carboxylic acid modification totally abolished the activity. A carboxylic acid was better than an N-
heptane acetamide at C-28. In the cancer prevention assay, compound 121 showed the strongest 
inhibition in EBV-EA activation, and was more potent than curcumin, even at low concentrations. 
The SAR trends were similar to those for anticancer activity, except that a C-3 carboxylic acid was 
preferred. In the anti-HIV assay, only compound 119 with an ε-lactone A-ring and 28-N heptane 
acetamide showed weak activity, and was identified as an entry inhibitor. However, its activity was 
weaker than a known entry inhibitor, A43-D, with the same C-28 side chain. 
 
 
v 
 
 
ACKNOWLEDGEMENTS 
 
First, my sincere gratitude and respect are extended to my mentor, Dr. Kuo-Hsiung Lee for 
his sage guidance, warm encouragement, and continuous support during my graduate studies and 
research. 
I am especially grateful to the members of my doctoral committee: Dr. Chin-Ho Chen, Dr. 
Jian Liu, Dr. Kyoko Nakagawa-Goto, and Dr. Qisheng Zhang for their advice, criticism, and 
encouragement.  
I am especially thankful to Dr. Kyoko Nakagawa-Goto for mentoring my experimental skills 
and generous sharing of her experiences in medicinal chemistry research either in the concept of 
developing a good paper or the direction of modification. 
I am especially grateful to Dr. Kenneth F. Bastow, Dr. Emika Ohkoshi, and Chia-Ya Wang 
for the cytotoxicity assay and chemosensitizing assays, to Dr. Harukuni Tokuda, Dr. Akira Iida, and 
Dr. Nobutaka Suzuki for their contributions to in vivo EBA-EA inhibition and in vivo two-stage 
mouse skin carcinogenesis assays, and to Dr. Chin-Ho Chen for anti-HIV assay and interpretation of 
the results. 
I am very grateful to Dr. Susan Morris-Natschke for her great help for the preparation of 
papers and this dissertation.  
My thanks are also extended to all the faculty and staff members, students, and especially 
current or former colleagues of Dr. Lee’s laboratory for their support and help. Besides, I also thank 
my roommate, Ying-Hsuan Lin, and all of my friends for their kindness and warmness friendship 
support. Finally, I thank my parents for their warmth support of my passion for researches. 
vi 
 
 
TABLE OF CONTENTS 
 
ABSTRACT  .................................................................................................................................... iii 
ACKNOWLEDGEMENTS .................................................................................................................. v 
TABLE OF CONTENTS ..................................................................................................................... vi 
LIST OF TABLES ................................................................................................................................ x 
LIST OF FIGURES .............................................................................................................................. xi 
LIST OF SCHEMES .......................................................................................................................... xiii 
LIST OF SYMBOLS AND ABBREVIATIONS ............................................................................... xiv 
 
Chapter 1. Origin, Synthesis, and Bioactivities of DDB-related Compounds on Cancer 
Chemosensitization, Cancer Prevention, and Anti-HIV Activity  ........................ 1 
1.1 Origin and Synthesis of Dimethyl Diphenyl Bicarboxylate (DDB) ............................ 1 
1.2 DDB-related Compounds and Their Bioactivities ...................................................... 3 
1.3 Cancer Resistance and Chemosensitization ................................................................ 9 
             1.3.1  Chemotherapeutic Resistance ............................................................................ 9 
             1.3.2  Chemosensitization.......................................................................................... 11 
             1.3.3  Chemosensitizing Potential of DDB and Bicyclol .......................................... 12 
1.4 Cancer Prevention ..................................................................................................... 15 
             1.4.1  Introduction of Cancer Prevention .................................................................. 15 
             1.4.2  Cancer Preventive Potential of DDB ............................................................... 16 
1.5        References ................................................................................................................. 18 
 
vii 
 
Chapter 2. Introduction of Betulinic Acid on the Researches of Anti-HIV Activity, 
Anticancer Activity, and Cancer Prevention ........................................................ 21 
2.1 Introduction of Betulinic Acid and Bevirimat ........................................................... 21 
2.2 HIV Life Cycle and Possible Drug Targets ............................................................... 22 
2.3 Progression of Betulinic Acid Modification on Anti-HIV research .......................... 24 
2.3.1   C-3 Position ................................................................................................... 24 
2.3.2   C-28 Position ................................................................................................. 25 
2.3.2   Bi-functional Modification: C-3 and C-28 .................................................... 25 
2.4 Progression of Betulinic Acid Modification on Anticancer Research ...................... 26 
2.4.1   C-3 Position ................................................................................................... 27 
2.4.2   Ring-A Modification ..................................................................................... 27 
2.4.3   C-28 Position ................................................................................................. 28 
             2.5        Progress of Betulinic Acid Modification on Cancer Prevention Research ................ 28 
2.6 References ................................................................................................................. 30 
 
Chapter 3. Non-toxic Dimethyl-4,4-dimethoxy-5,6,5,6-dimethylenedioxybiphenyl- 
2,2-dicarboxylate (DDB) Analogs Chemosensitize Multidrug Resistant  
Cancer Cells to Clinical Anticancer Drugs ........................................................... 34 
 
3.1 Introduction ............................................................................................................... 34 
3.2 Design and Synthesis................................................................................................. 36 
3.3 Results and Discussion .............................................................................................. 39 
3.4 Conclusions ............................................................................................................... 50 
3.5 Materials and Methods .............................................................................................. 53 
3.6 References ................................................................................................................. 63 
 
Chapter 4. Novel Analogs of Dimethyl Dicarboxylate Biphenyl as Potent Cancer 
Chemopreventive Agents ........................................................................................ 65 
viii 
 
4.1 Introduction ............................................................................................................... 65 
4.2 Results and Discussion .............................................................................................. 67 
4.3 Conclusions ............................................................................................................... 73 
4.4 Materials and Methods .............................................................................................. 73 
4.5 References ................................................................................................................. 79 
Chapter 5. A-ring Modification of Betulinic Acid for Novel Cancer Preventive,  
Anticancer and Anti-HIV Agents .......................................................................... 81 
 
5.1 Introduction ............................................................................................................... 81 
5.2 Design and Synthesis................................................................................................. 82 
5.3 Results and Discussion .............................................................................................. 85 
             5.3.1  Results of Cytotoxicity Activity ...................................................................... 85 
             5.3.2  Results  of Cancer Preventive Activity............................................................ 86 
             5.3.3  Result of Anti-HIV Activity ............................................................................ 87 
5.4 Conclusions ............................................................................................................... 88 
5.5 Materials and Methods .............................................................................................. 89 
5.6 References ................................................................................................................. 95 
 
Chapter 6. Concluding Remarks and Perspectives for Future Directions of Research 
 on DDB and BA Derivatives  ................................................................................. 97 
 
6.1    DDB as a Promising Lead for Cancer Prevention and Chemosensitization .............. 97 
6.1.1   SAR Conclusions of DDB Analogs as a Lead for Chemosensitization 
           and Cancer Prevention .................................................................................. 97 
 
6.1.2   Design, Synthesis of DDB Analogs as Novel Chemosensitizers .................. 98 
 
6.1.3    Design, Synthesis of DDB Analogs as Novel Chemopreventive  
            Agents......................................................................................................... 100 
 
6.2    A-ring Modification of Betulinic Acid Derivatives ................................................ 101 
6.2.1   SAR Conclusions of A-ring Opened Betulinic Acid Derivatives ............... 101 
6.2.2   Future Research Direction of A ring Opened Betulinic Acid  
ix 
 
            Derivatives ................................................................................................. 102 
 
6.2.3   Successful Built Up Six Member Ring BA Derivatives ............................. 104 
6.2.3.1  Introduction ............................................................................................... 104 
6.2.3.2  Synthesis of the Six Ring BA Derivative .................................................. 106 
6.2.4  Future Research Direction of F-ring BA Derivative Modification .............. 109 
6.2.4.1  Optimize Cyclization Condition and Complete Dehydration of β-
Hydroxyketone .......................................................................................... 109 
6.2.4.2  New F-ring BA derivatives ....................................................................... 109 
6.3 References ............................................................................................................... 111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
 
LIST OF TABLES 
 
Table 1.1   Anti-HIV Activities of Brominated Biphenyl Derivatives in Acutely  
                  Infected H9 Lymphocytes ....................................................................................... 5 
 
Table 1.2   Effect of 2,2-Disubstituted Biphenyls on CCl4-induced Liver Injury in 
                   Mice ........................................................................................................................ 6 
 
Table 1.3   Cytotoxic asymmetric biphenyls  ............................................................................ 7 
Table 1.4   Furoxan-based Nitric Oxide-releasing DDB Derivatives and Their Anti-
proliferative Activity against HepG2 and Their MDR Reversal Activity 
                  against MCF-7/Adr .................................................................................................. 8 
 
Table 1.5   Effect of DDB on the sensitivities of MCF-7, MCF-7/Adr, Bel7402, KB and 
                  KBvin to VCR, DOX and TAX ............................................................................ 13 
 
Table 1.6  FDA-Approved Chemoprevention Drugs .............................................................. 16 
Table 2.1  In vitro Cytotoxic Effect of Betulinic Acid on Human Cancer Cell Lines ............ 26 
Table 2.2  BA Derivatives for Cancer Preventive Activity ..................................................... 29 
Table 3.1  Cytotoxicity of DDB Analogs ................................................................................ 41 
Table 3.2  CLogP Values of Synthesized Compounds 1 and 69-103 ...................................... 41 
Table 3.3  Reversal Effects with Paclitaxel (TAX), Vincristin (VCR), and  
                 Doxorubicin (DOX) in KBvin ................................................................................ 45 
 
Table 4.1  DDB Analogs and Their EBV-EA Inhibition Ability ............................................ 69 
Table 4.2  In vivo inhibitory effects of 83, 85 and 106 on two-stage mouse 
                 carcinogenesis......................................................................................................... 71 
 
Table 5.1  Cytotoxicity of BA A-ring Opened Derivatives  .................................................... 86 
Table 5.2  EBV-EA Inhibition Ability of Betulinic Acid Derivatives .................................... 87 
Table 6.1  Basic Cyclization Conditions of 128 .................................................................... 109 
 
xi 
 
 
LIST OF FIGURES 
 
Figure 1.1   Structure of DDB and Dibenzocylcooctadiene Lignans ........................................ 2 
Figure 1.2   Structures of Regioisomers of DDB ...................................................................... 2 
Figure 1.3   Regio-selective Synthesis of α-DDB ..................................................................... 3 
Figure 1.4   DDB Derivatives with Different 1,2,3-Substituted Thiadiazole Moieties ............. 7 
Figure 1.5   Schematic Strategy of Eliminating Stem Cell-like Features (CSC) Cancer 
                    Cells ....................................................................................................................... 9 
 
Figure 1.6   Schematic Representation of the Main Cellular Mechanisms of  
                   Chemoresistances. ................................................................................................ 11 
 
Figure 2.1   Structures of Betulinic Acid and Bevirimat ......................................................... 22 
Figure 2.2   HIV Replication Cycle ......................................................................................... 23 
Figure 2.3   Selected BA Derivatives on C-3 Position for Anticancer Activity ...................... 27 
Figure 2.4   Selected BA Derivatives on A-ring Modification for Anticancer Activity.......... 28 
 
Figure 3.1   Structures of DDB, Bicyclol and Dibenzocyclooctadiene Lignans ..................... 36 
Figure 3.2   Screening of Reversal Abilities against KB (A) and KBvin (B) .......................... 42 
Figure 3.3   Dose-response of Growth Inhibition of 73 and 90 by Paclitaxel,  
                    Vincristine and Doxorubicin against KB and KBvin .......................................... 46 
 
Figure 3.4  Dose –response Effect of Compounds 73 and 90 on Sensitization of  
                   KBvin to TAX ...................................................................................................... 48 
 
Figure 3.5  Effect of Compounds on P-gp Function in KBvin Cells ....................................... 49 
Figure 3.6   Recovered Doxorubicin Accumulation in DDB Analog-treated Drug  
                   Resistant KBvin cells ........................................................................................... 50 
 
Figure 3.7   Summary of Structure-and-Activity Relationship................................................ 52 
Figure 4.1   Structures of DDB and Schisandrin C ................................................................. 66 
xii 
 
Figure 4.2   Syntheses of DDB Analogs .................................................................................. 70 
Figure 4.3   Inhibitory Effects of Compounds 83, 85 and 106 on DMBA-TPA Mouse 
                    Skin Carcinogenesis ............................................................................................ 72 
 
Figure 4.4  Pictures of Tested Rat of In Vivo Two Stage Mouse Skin Carcinogenesis 
                   Assay. ................................................................................................................... 72 
 
Figure 5.1  Structure of A43-D................................................................................................ 88 
Figure 6.1  Proposed Rigid BA Analog ................................................................................. 105 
 
Figure 6.2  N-4-Hydroxy Pyrimidine Nucleoside and Related Bicyclic Analogs ................. 106 
 
Figure 6.3   Two Synthetic Methods of Forming β-Keto Nitrile BA  
                    Derivative (128) ................................................................................................. 107 
 
Figure 6.4  Explanation of Stereo-conformation of C-3 Nitrile Group of 129 ...................... 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
 
LIST OF SCHEMES 
 
Scheme 3.1  Syntheses of Diester DDB Derivatives 70-95..................................................... 38 
Scheme 3.2  Syntheses of Dihalogenated DDB Analogs ........................................................ 39 
Scheme 5.1  Synthetic Scheme of BA A-ring Modification Derivatives ................................ 84 
Scheme 6.1  Proposed Synthetic Pathway and Substitutions of 2,2-Methylester DDB   
Analogs .............................................................................................................. 99 
 
Scheme 6.2  Proposed Synthetic pathway for 2,2-methylene Amide DDB Analogs ........... 100 
 
Scheme 6.3  Proposed DDB Analogs and Synthetic Pathway for Cancer Prevention .......... 101 
Scheme 6.4  Proposed BA Derivatives for Cancer Prevention ............................................. 103 
Scheme 6.5  Proposed New BA Derivatives for Cytotoxicity .............................................. 103 
Scheme 6.6  Proposed New BA Derivatives for anti-HIV Activity and Their Synthetic 
Scheme ............................................................................................................. 104 
 
Scheme 6.7  Synthetic Scheme of the F-ring BA Derivative ................................................ 108 
 
Scheme 6.8  Proposed New F-ring BA Derivatives and Their Synthetic Route ................... 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
 
LIST OF SYMBOLS AND ABBREVIATIONS 
 
BA Betulinic acid 
DBDMH 1,3-dibromo-5,5-dimethylhydantoin 
DDB 
dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl- 
2,2′-dicarboxylate 
DMAP               4-dimethylaminopyridine 
DMF                N,N-dimethylformamide 
DMSO               dimethyl sulfoxide 
EBV-EA Epstein Barr virus early antigen 
EC50                 effective dose which causes 50% inhibition 
FDA                Food and Drug Administration 
1H NMR           proton nuclear magnetic resonance 
MDR            Multi-drug resistance 
MeOH               methanol 
mp                 melting point (°C) 
MS                mass spectrum 
TPA 12-O-tetradecanoyl phorbal 13-acetate 
μM                   micromolar concentration 
WHO                  World Health Organization 
 
 
 
  
 
Chapter 1  
Origin, Synthesis, and Bioactivities of DDB-related Compounds on Cancer 
Chemosensitization, Cancer Prevention, and Anti-HIV Activity 
 
1.1 Origin and Synthesis of Dimethyl Diphenyl Bicarboxylate (DDB) 
The Chinese herb Schisandra chinesis Baill (Schisandraceae), Wu Wei Zi, has been used as a 
bactericidal agent as well as to treat other reported indications, such as chronic cough and dyspnea, 
diarrhea, night sweats, wasting disorders, irritability, palpitations, and sleep disorders. Several 
dibenzocylcooctane ligans have been isolated from Wu Wei Zi, including schisandrin A, schisandrin 
B, schisandrin C, and gomisin A (Figure 1.1).
1
 Schisandrin B and schisandrin C, the two most 
investigated constituents in Schisandra chinesis, account for the therapeutic effects in liver diseases.
2
  
The biphenyl unit of these lignans is critical for their pharmacological activities. Dimethyl-4,4′-
dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate (DDB, 1) was found as a synthetic 
intermediate derivative of schisandrin C (Figure 1.1). Different acronyms for DDB, including 
diphenyl dimethyl bicarboxylate, biphenyl dimethyl dicarboxylate (BDD)
3
, and diphenyl dimethyl 
dicarboxylate (PMC), are used in the literature.
4
  
 
 
 
 
 2 
 
Figure 1.1 Structures of DDB and Dibenzocylcooctadiene Lignans 
 
DDB shares the biphenyl partial structure of dibenzocyclooctadiene lignans, but lacks the 
cyclooctadiene ring. The three regioisomers of DDB (α-, β- and γ-DDB) are shown in Figure 1.2. 
Because different structures can display different biological activities, DDB as a hepatoprotectant 
generally referred to α-DDB.  The two regioisomers, β-DDB and γ-DDB, were found as by-products 
during the synthesis of α-DDB.  
Figure 1.2 Structures of Regioisomers of DDB. 
 
 
 
 
 
     
α-DDB was synthesized regio-selectively from commercially available and inexpensive methyl 
gallate (Figure 1.3).
5, 6
 Selective methylation with methyl sulfate through a borax-chelated transition 
state, followed by ortho-hydroxy-directed regioselective bromination with 1,3-dibromo-5,5-
dimethylhydantoin (DBDMH) gave methyl 2-bromo-3,3-dihydroxy-5-methoxybenzoate. After 
 3 
 
protection of the diol as a methylene acetal, homocoupling of the resulting phenylbromide under 
Ullmann conditions produced α-DDB in 25% overall yield. 
Figure 1.3 Regio-selective Synthesis of α-DDB 
 
1.2 DDB-related Compounds and Their Bioactivities 
DDB is now used as an adjuvant hepatoprotectant in China and other Asian countries for the 
treatment of chronic viral hepatitis and other liver diseases.
7
 DDB itself also exhibits many 
pharmacological effects as listed below. 
(1) Hepatoprotectant: DDB in clinical research has been shown to lower levels of serum alanine 
aminotransferase (ALT), bilirubin, and α-fetoprotein in patients and to alleviate symptoms in 
patients with chronic viral hepatitis.
7
 Serum aspartate aminotransferase (AST) and ALT are 
commonly used biomarkers for liver function. Elevated serum AST and ALT, resulting from 
these enzymes being released into blood circulation from the cytosol of hepatocytes, can be 
seen upon hepatocellular damage. In an in vitro study, DDB treatment affected synthesis 
and/or degradation of ALT in cultured hepatocytes, resulting in decrease of cellular ALT.
8, 9
 
However, in some clinical studies, no improvement was seen in the histological grade or 
stage of liver disease,
10
 which implied that DDB can only decrease the level of liver enzymes, 
such as ALT. Therefore, DDB is not suitable for the routine treatment of chronic liver 
diseases, especially in anti-HBV therapy, because the ALT level is the only marker to 
monitor the anti-viral efficacy. Another study showed that DDB can reduce tamoxifen-
induced liver toxicity by increasing the activity of anti-oxidant enzymes and decreasing 
glutathione level and lipid peroxides. Interestingly, the protective effect of DDB (treated 
 4 
 
before tamoxifen intoxication) was less significant than its curative effect against tamoxifen-
induced liver injury, which suggested that DDB might have a curative effect on liver 
damage.
11
 
(2) Anti-HBV: Although DDB is usually prescribed as an adjuvant agent for viral hepatitis, a 
recent study showed that DDB may contribute to the anti-HBV effect by stimulating Jak/Stat 
signaling and inducing the expression of interferon alpha (IFN-α) stimulated genes, mostly 6-
16 and ISG12.
12
 
(3)  Prevention of immunotoxicity:  In two different studies, DDB restored cellular immune 
function suppressed by carbon tetrachloride (CCl4) and ketoconazole, which likely leads to 
decreased numbers of natural killer cells and phagocytic activity in mice.
4, 13
 In addition, 
DDB also reversed humoral immunosuppression caused by ethanol in mice.
14
 
(4)  Chemosensitization: DDB exhibited multidrug resistant (MDR) reversal ability in MDR 
breast carcinoma MCF-7/Adr cells, KBv200, and intrinsic MDR human hepatocarcinoma 
Bel7402 cells via inhibition of P-gp and enhancement of apoptosis. At doses of 300 and 500 
mg/kg, co-treatment with DDB and vincristine (VCR) in nude mice bearing KBv200 
xenografts also enhanced antitumor activity.
15
   
(5)  Chemoprevention: At doses of 1, 2, and 4 µmol/L, DDB exhibited a preventive effect on 
oncogenic transformation of WB-F344 (rat liver epithelial) cells induced by 3-
methylcholanthrene and 12-O-tetradecanoyl phorbal 13-acetate (TPA). In a soft-agar colony 
formation assay to examine the ability of cells to grow unattached, colony numbers were 
reduced in transformed cells treated with DDB. Furthermore, DDB inhibited TPA-induced 
down-regulation of the gap junctional intercellular communication (GJIC), a process 
commonly seen in transformed cells. These findings suggested that DDB prevented 
oncogenic transformation of WB-F344 cells.
16
 
 
 
 5 
 
Besides DDB itself, DDB derivatives also show various bioactivities as summarized below. 
(1) Anti-HIV activity: Sixteen 3, 3′-dibromo-DDB derivatives were reported, and their structures 
and activities are summarized in Table 1.1. Among all 16 compounds, 3,3′-dibromo-DDB (3) 
was the most potent (EC50= 0.23 µg/ml, Therapeutic Index > 480), and reverse transcriptase 
was the possible biological target. SAR study suggested that the types of substituents on the 
phenolic hydroxy groups were more important than the number of bromine(s) on the aromatic 
rings.
17
 
Table 1.1. Anti-HIV Activities of Brominated Biphenyl Derivatives in Acutely Infected H9 
Lymphocytes 
compd  R1 R2 R3 R4 EC50 
(μg/ml) 
TIa 
1  
 
  
 
H H COOCH3 COOCH3 5 >20 
2  
 
 
 
 
Br 
H COOCH3 COOCH3 0.52 >190 
3  
 
 
 
Br 
COOCH3 COOCH3 0.23 >480 
4 COOH COOH >100 1 
5 COO(CH2)5CH3 COO(CH2)5CH3 2 >50 
6 CO-O-CO - - 
7 COO- 
COO- ( )2 
17 >1.2 
<5.9 
8 COOH COOCH2CH3 60 >1.7 
9 COOH COO(CH2)2N
+(CH3)3Cl
- >100 1 
10 COOH 
 
30 >3.3 
11 COOH 
 
>100 1 
12 COO-Na+ COO-Na+ >100 1 
13 COO-Na+ COOC2H5 - - 
14  
 
Br H COOCH3 COOCH3 >100 1 
15 Br Br COOCH3 COOCH3 >100 1 
16 Br H CH2OH CH2OH 100 >1 
17 Br Br CH2OH CH2OH >100 1 
a
TI (therapeutic index) is calculated by EC50/IC50. IC50 of all sixteen compounds was >100 μg/ml, 
except 7 (IC50 >20 μg/ml). 
 
 6 
 
(2) Protective effect on CCl4-induced liver injury: 2,2′-Disubstituted DDB analogs exhibited 
suppressive effects on CCl4-induced liver injury. The 2,2′-disubstituted unsymmetric 
biphenyls were synthesized by intramolecular Ullman coupling. Their structures and in vitro 
suppressive activity on CCl4-induced liver injury are summarized in Table 1.2. Compounds 
18, 21, 28, and 30 showed potent suppressive effects and were further evaluated in vivo in 
mice at the doses of 100, 30, and 10 mg/kg body weight. Among all tested compounds, 
compound 30 was the most potent and exhibited no acute toxicity.
18
 
Table 1.2. Effect of 2,2′-Disubstituted Biphenyls on CCl4-induced Liver Injury in Mice 
Compd  R1 R2 Suppressive 
activity
a
 
1 
(DDB) 
   +++ 
18  
 
 
OEt OEt ++++ 
19 -O(CH2)3O- - 
20 NHEt NHEt +++ 
21 NEt2 NEt2 ++++ 
22 NHC(Me)2CH2OH NHC(Me)2CH2OH +++ 
23 NEt2 OEt ++ 
24 NEt2 O-(2-Me-Ph) +++ 
25 NHC(Me)2CH2OH O-(2-Me-Ph) ++ 
26 NHCH2CH2OH O-(2-Me-Ph) + 
27 NH(CH2)5CH3 O-(2-Me-Ph) ++ 
28 
 
O-(2-Me-Ph) ++++ 
29 
 
O-(2-Me-Ph) + 
30 O-(2-Me-Ph) NHC(Me)2CH2OH ++++ 
31 O-(2-Me-Ph) 
 
++ 
a
Suppression (%) of the CCl4-induced elevation of GPT in mice: –  20, 20  +  40, 40  ++  60, 
60  +++  80, 80  ++++. 
  
(3) Anticancer activity: DDB derivatives bearing different 1,3,4-thiadiazole moiety (Figure 1.4) 
were investigated for cytotoxic activity against five human cancer cell lines: HepG2 (human 
hepatoma cells), KB (human oral epidermoid cancer cells), A549 (human lung carcinoma 
 7 
 
cells), K562 (human chronic myeloid leukemia cells), and MCF-7 (human breast cancer 
cells). The two most active compounds contained a sulfone linkage and 3- or 4-substituted 
nitrobenzene ring, and exhibited IC50 values of 6.6 / 6.9 µM for HePG2, 19.2 / 18.9 µM for 
KB, 8.9 / 9.9 µM for A549, 7.1 / 6.4 µM for K562, and 12.6 / 11.8 µM for MCF-7, 
respectively.
19
  
Figure 1.4. DDB derivatives with different 1,3,4-substituted thiadiazole moieties. 
 
 
Other research studied a series of unsymmetric biphenyls for cytotoxic activity against 
DU145 (prostate cancer), A549 (lung cancer), KB (nasopharyngeal) and KBvin (KB 
multidrug resistant cell) cell lines. Table 1.3 lists the structures and cytotoxic activities of 
several potent compounds. Compounds 33, 35, and 36 showed potent activity within an  IC50 
range of 0.04 – 3.23 µM. SAR study showed that it is critical to have a bulky group on the 
2,2′-position of the biphenyl skeleton.20 
 
Table 1.3. Cytotoxic Asymmetric Biphenyls 
 
 
 
 
IC50 (µM) 
Compd Type R1 R2 DU145 A549 KB KBvin 
32 I COOMe CHO 5.25 7.76 12.0 4.97 
 8 
 
33 I CH=C(Me)NO2 CH=C(Me)NO2 NT 0.11 0.41 0.51 
34 II CHO CHO 3.66 20.2 15.7 4.10 
35 II CH2OCOPh CH2OCOPh 0.04 0.04 0.04 0.04 
36 III COOMe CHO 0.31 1.70 3.23 0.86 
37 IV COOMe CHO 2.23 19.6 12.8 1.88 
 
(4) Chemosensitizing activity: Several novel furoxan-based nitric oxide (NO)-releasing DDB 
derivatives were synthesized and tested for anti-proliferative activity and chemoreversal 
activity in HepG2 and MCF-7/Adr multidrug resistant cell lines, respectively (Table 1.4). 
Increased intracellular doxorubicin concentrations were observed resulting from inhibition for 
P-gp-mediated drug efflux and downregulation of P-gp expression.
21
 
Table 1.4. Furoxan-based Nitric Oxide-releasing DDB Derivatives and Their Anti-proliferative 
Activity against HepG2 and Their MDR Reversal Activity against MCF-7/Adr. 
 
 
 
 
 
 
IC50 
(µM) 
Compd R1 R2 HepG2
a
 MCF-7
b
 
(+ DOX
c
) 
MCF-7/Adr
b
 
(+ DOX
c
) 
38 -O(CH2)2- -(CH2)2- 1.35 - - 
39 -O(CH2)3- -(CH2)2- 1.14 - - 
40 -O(CH2)4- -(CH2)2- 1.36 - - 
41 -NH(CH2)2- -(CH2)2- 1.25 - - 
42 -O(CH2)2O(CH2)2- -(CH2)2- 1.88 - - 
43 -OCH(CH3)(CH2)2- -(CH2)2- 1.15 - - 
44 -OC(CH3)2(CH2)2- -(CH2)2- 1.36 - - 
45 -O(CH2)3- -CH3CH- 1.25 - - 
46 -O(CH2)4- -CH3CH- 1.21 0.224 (0.1 µM) 
0.066 (   1 µM) 
0.026 (10 µM) 
46.28 (0.1 µM) 
23.17 (   1 µM) 
0.26 (10 µM) 
47 -O(CH2)2O(CH2)2- -CH3CH- 1.49 0.183 (   1 µM) 
0.155 (10 µM) 
9.98 (   1 µM) 
0.41 (10 µM) 
DDB   >100 0.287 (0.1 µM) 
0.271 (   1 µM) 
0.259 (10 µM) 
32.29 (0.1 µM) 
19.08 (   1 µM) 
16.15 (10 µM) 
5-FU   15.92   
a. Anti-proliferative assay for HepG2 cell line. b. Chemosensitizing assay: MTT assay was applied to examine the cell viability of co-treatment of 
compounds and doxorubicin. C. DOX: doxorubicin 
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1.3 Cancer Resistance and Chemosensitization 
1.3.1. Chemotherapeutic Resistance 
Although immense effort has been put on cancer research, cancers still remain among the leading 
causes of death in the US. Chemotherapy, a critical therapeutic strategy for cancer treatment, fails to 
eliminate all tumor cells associated with cell-intrinsic processes or acquired drug resistance, the most 
common cause of tumor recurrence. Emerging evidence suggests that epithelial-mesenchymal 
transition (EMT)-type cells and cancer stem cells (CSCs) or initiating cells are more resistant to 
conventional chemotherapy and are linked to anticancer drug resistance.
22
 During acquired drug 
resistance, the occurrence of reversible epigenetic changes imply different differentiation states of the 
tumor, reflecting EMT and the presence of stem cell-like chemo-refractory cells. A schematic strategy 
for eliminating stem cell-like cancer cells is shown in Figure 1.5. Because conventional anticancer 
drugs can only eliminate bulk differentiated cancer cells, a combination of selectively targeted CSC 
agents and current chemotherapeutic agents is preferred. Several drug targets have been identified, 
such as histone deacetylase and transforming growth factor beta 1 (TGF-β) pathways. Inhibitors of 
these pathways prevent cell differentiation or kill CSCs.
22
  
Figure 1.5. Schematic Strategy of Eliminating Stem Cell-like Features (CSC) Cancer Cells.
22
 
Drug X is a chemotherapeutic agent that can kill bulk differentiated tumor cells, while Drug Y either 
acts as a chemosensitizer to prevent tumor cells from undergoing EMT to become stem cell-like 
resistant cancer cells or directly and selectively kill CSCs.                      
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Another issue of chemotherapeutic resistance is the tumor microenvironment, in which cancer 
cells are surrounded by various sets of non-transformed cells and a heterogenous stromal 
compartment.
23
 The interaction between tumor cells and normal cells in this tumor microenvironment 
occurs via secreted and surface-bound proteins, and is critical for tumor progression. Firstly, the 
tumor cells can use the general stress-induced secretory machinery to survive and progress after 
administration of frontline chemotherapy. This finding is supported by the evidence that within 24 
hours of treatment with doxorubicin in the thymus, interleukin 6 (IL-6), which conferred resistance to 
the drug, was released from endothelial cells, which can sense DNA damage and acutely activate a 
protective secretory program for both normal cells and tumor cells. Secondly, increased physical 
barriers to drug accessibility have evolved to affect cancer treatment by paracrine prosurvival 
signaling of factors such as IL-6. A strategy to eliminate the interference from the tumor 
microenvironment and improve the outcome of chemotherapy is to combine current chemotherapeutic 
agents with prosurvival signaling inhibitors, which may potentiate the killing effect of anticancer 
agents.
24
 
In addition to the tumor microenvironment, cancer cells also adapt other mechanisms to deal with 
chemotherapeutic agents. Cellular mechanisms of multidrug resistance include decreased uptake of 
chemotherapeutic agents, such as expression of vacuolar ATPase (V-ATPase), or adaptation of cancer 
cells to affect the cytotoxic ability of chemotherapeutic agents, such as down-regulation of the drug 
target (e.g., topoisomerase II), over-expression of metabolizing enzymes (e.g., glutathione S-
transferase π-1 or -2 (GST p-1 / p-2), heterdimerization and receptor cross-activation for decreasing 
activity of receptor kinase inhibitors, and microtubule dynamic changes.  Over-expression of drug 
efflux transporters such as P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) 
is the primary cause leading to multidrug resistance.
25
  A cartoon summarizing cellular mechanisms 
of cancer drug resistance is shown below (Figure 1.6).
26
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Figure 1.6. Schematic Representation of the Main Cellular Mechanisms of Chemoresistances. 
 
1.3.2. Chemosensitization 
Chemosensitization is one strategy to overcome chemotherapeutic resistance. The concept of 
chemosensitization is to administrate another agent to enhance the activity of current 
chemotherapeutic agents.
27
 Great efforts have been put into developing chemosensitizing agents, 
categorized as apoptosis modulators and efflux pump inhibitors. A new research area in 
chemosensitization is the differentiation of CSCs into epithelial-like cancer cells. Several drug targets 
for differentiation of CSCs have been mentioned above. Over-expression of efflux pumps on the 
surface cell membrane, which results in resistance to different structural and functional anticancer 
drugs, accounts for most multidrug resistance. Drug efflux is mediated by ATP-dependent multidrug 
transporters including multidrug resistance protein (MDR, P-glycoprotein, P-gp), multidrug resistance 
associated protein (MRP1), lung resistance-related protein (LRP), and breast cancer resistance protein 
(BRCP). Two first generation MDR reversal agents, verapamil and cyclosporine A, are usually used 
 12 
 
in MDR research as positive controls.  However, they were precluded from clinical use due to their 
significant toxicity. Additional MDR modulators were discovered as second or third generation 
agents; however, unsatisfactory toxicity and pharmacokinetic issues still impeded their further 
development.  Although several third generation P-gp inhibitors, including Tariquidar, are in phase III 
clinical trial for breast cancer, the existing MDR inhibitors are not yet in clinical use.   
Natural products have been proven to be an important source for drug discovery. More than 60 % 
of the current anticancer drugs are from natural products. Several favorable features including multi-
targeting properties, low cost, low toxicity, and immediate availability have led to increased interest 
in and discovery of natural products as anticancer drugs over the years.
28
 One example is resveratrol, 
3,4′,5-trihydroxy-trans-stilbene, first isolated from the roots of white hellebore (Veratrum 
grandiflorum O. Loes). Since the first article on its anticancer potential was published in 1997, 
resveratrol has been significantly investigated. Its anticancer activities are mediated through 
modulation of cell cycle progression, inflammation, proliferation, apoptosis, invasion, metastasis, and 
angiogenesis of tumor cells. Resveratrol also acts as a chemosensitizer by modulating apoptotic 
pathways, down-regulating drug transporters, and down-regulating proliferative proteins in NF-κB 
and STAT3 pathways.
29
 
1.3.3 Chemosensitizing Potential of DDB
15
 and Bicyclol
30
 
Like resveratrol, DDB, a synthetic intermediate derivative of schisandrin C, also exhibited 
chemosensitizing effects on multidrug resistant cancer cell lines. Table 1.5 summarizes the 
chemoreversal effects of DDB on MCF-7 (breast cancer), MCF-7/Adr (multidrug-resistant breast 
cancer), Bel7402 (human hepatocellular carcinoma), KB (human nasopharyngeal carcinoma), and 
KBvin (vincristine-selected KB MDR subline) cell lines. At non-toxic concentrations of 12.5, 25, and 
50 µM, DDB markedly enhanced the sensitivity of MCF-Adr and KBvin cells to vincristine (VCR) 
and doxorubicin (DOX) in a dose-dependent manner. The chemosensitizing ability was also seen in 
an innate MDR cell line, Bel7402. Moreover, increased cellular doxorubicin concentration (2 to 2.9 
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fold) was found in DDB treated groups at the doses of 25 and 50 µM, respectively, but this increase 
was seen only in an MDR resistant subline such as MCF-Adr. When detecting the surface expression 
of P-gp by fluorescence, the fluorescence intensity of P-gp on the surface of MCF-Adr cells was 
much higher than that on sensitive MCF-7 cells, as expected. After MCF-7/Adr cells were exposed to 
25 and 50 µM of DDB, the fluorescence intensity of surface P-gp decreased markedly, indicating that 
DDB inhibited P-gp levels in resistant cells. The expression level of mdr1, a gene encoding P-gp 
expression in MCF-7 cells, was examined by semi-quantitative RT-PCR. As expected, the mdr1 band 
could be observed clearly in resistant MCF-7/Adr cells, while no band was seen in the MCF-7 group. 
However, no decrease in mdr1 RNA levels was seen in MCF-7/Adr cells treated with DDB for 24 h.
15
  
Table 1.5. Effect of DDB on the Sensitivities of MCF-7, MCF-7/Adr, Bel7402, KB and KBvin to VCR, 
DOX and TAX. (VRP= verapamil) 
 
In addition, KB and KBv200 xenografts were implanted in both flanks of nude mice to 
investigate the in vivo MDR reversal activity of DDB. Injection of VCR alone for 16 days inhibited 
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about 40 % of the growth of KB xenografts, but did not affect the growth of KBv200 xenografts, 
which is a sign of resistance. However, co-treatment of DDB with VCR at 300 and 500 mg/kg body 
weight markedly potentiated the antitumor effect of VCR on KBv200 xenografts, but had only a 
slight effect on KB xenografts.  
A major challenge in developing clinical useful MDR reversal agents is that such agents would 
affect the clearance of chemotherapeutic agents. The pharmacokinetics of DDB with DOX were 
studied by measuring DOX concentration in plasma and tumor tissues of ICR mice bearing S180 
sarcoma. Similar values were found for the area under curve for 24 hrs (AUC0−24 h) of DOX alone and 
DOX plus DDB in plasma, indicating that co-administration of DDB did not affect the 
pharmacokinetics of DOX. A higher Dox concentration in tumor tissues was also found in the DDB 
plus DOX group compared with the DOX alone group. 
Moreover, bicyclol, a second generation hepatoprotectant used in China, 
also showed chemosensitizing effects in Kbvin and MCF-7/ adr cell lines.
30
 
The fold of reversal for vincristine in the Kbvin cell line was about 20 and 
for paclitaxel in the Kbvin cell line was about 13 and in the MCF-7 cell line 
was about 11. DDB and bicylcol have the same structure, except that one methylcarboxylate 
(COOCH3) group in DDB has been reduced to a hydroxymethylene group (CH2OH) in bicyclol, 
which could be a starting point for the design of DDB derivatives.  
To conclude, DDB possesses the features of low toxicity, easy synthesis, chemosensitizing effects 
in vitro as well as in vivo, and no alteration of DOX clearance, which suggests that DDB is a 
promising lead for further modification aimed at chemosensitizer development. 
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1.4 Cancer Prevention 
1.4.1 Introduction of Cancer Prevention 
    Cancer is a complex disease. A major focus of carcinogenesis research has been the issue of 
latency. Cancer is a multistep process, which often involves delayed development. As early as the 
1930’s, researchers were already investigating whether cancer involves multiple steps, but it was not 
until the publication of Berenblum and Shubik in 1947 that a model distinguishing the steps in 
carcinogenesis was actually demonstrated.
31
 This model described three different stages of cancer 
development: initiation, promotion, and progression. Initiation was an irreversible event that we now 
know involves permanent alteration in the DNA, whereas promotion was a reversible process that 
involved clonal expansion of initiated cells to form benign lesions. Another characteristic of initiation 
was that the effect appeared to be addictive, while promotion was not addictive. Progression would be 
the step that converts the benign lesions to malignancy.
32
 The concept of chemoprevention is to block 
each step to prevent cells from progressing to the next step.  Inhibition of the long and reversible 
promotion step has been widely studied, and is an effective approach to control cancer. Cancer 
chemoprevention is defined as the use of natural dietary compounds and/or synthetic substances that 
can delay, prevent, or even reverse the development of adenomas, as well as the progression from 
adenoma to carcinoma.
33
  Strategies for discovering cancer preventive agents can be summarized 
briefly into three categories: quenching inflammation (such as with aspirin), curbing premalignant 
cells (such as with a combination of TRAIL and RAc), and preventing metastasis (such as with 
genistein).
34
 Possible mechanisms of chemoprevention include cell cycle arrest and apoptosis or 
inhibition of signal transduction pathways including mitogen-activated protein kinases (MAPK), 
protein kinase C (PKC), phosphoinositide 3-kinase (PI3K), and glycogen synthase kinase (GSK).
35
 
Various phytochemicals, such as carotenoids, green tea polyphenols, curcumin, glycyrrhizin, and 
related compounds, from herbs and medicinal plants have been identified to exhibit cancer preventive 
ability.
36
 Besides these dietary phytochemicals, the US FDA has approved several drugs for cancer 
prevention, which is indicative of the emerging importance of this field (Table 1.6).  Because the 
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pathogeneses of cancers are different, prevention has to be specific in order to gain FDA approval. 
For example, tamoxifen and raloxifen, which are selective estrogen receptor modulators, have been 
approved for women with high breast cancer risk, and use of these two drugs can result in a 50% risk 
reduction.
34
  
Table 1.6. FDA-Approved Chemoprevention Drugs
34
.  
Drug Brand 
name(s) 
Cancer type Year first 
approved 
Target / mechanism Original 
manufacturer 
Tamoxifen Nolvadex 
Istubal  
Valodex 
Breast 1998 Selective estrogen receptor 
modulator (SERM) 
AstraZeneca 
Raloxifene Evista Breast 2007 SERM Eli Lilly 
HPV vaccine Gardasil 
Cervarix 
Cervix 
Vulva 
Vagina/Anus 
2006  Elicit immune response to 
prevent infection by the most 
common cancer-causing types 
of HPV  
Merck & Co 
GlaxoSmithKline 
Porfimer sodium 
+ photodynamic 
therapy (PDT) & 
omeprazole 
Photofrin Esophageal 2003 Lodges in precancerous cells 
and upon exposure to certain 
light produces an active form 
of oxygen that kills nearby 
cancer cells  
Axcan 
Fluorouracil Efudex 
Fluoroplex 
Carac 
Skin 1970 Interferes with DNA synthesis 
and leads to cell death 
Valeant 
Diclofenac 
sodium 3% 
Solaraze Skin 2000 Exact mechanism is unknown PharmaDerm 
5-aminolevulinic 
 acid + PDT* 
Levulan Skin 1999 Solution kills precancerous cell 
when exposed to light 
1
 
DUSA 
Imiquimod Aldara (5 %) 
Zyclara 
(3.75%) 
Skin 2004 Enhances immune response 
and promotes apoptosis 
Graceway 
Pharmaceuticals  
 
1.4.2 Cancer Preventive Potential of DDB
16
 
DDB was also tested for chemopreventive ability in three different experiments involving 
hepatocarcinoma. The first experiment was two stage chemical oncogenesis of WB-F344 (rat liver 
epithelial cells). WB-F344 cells were incubated in medium containing 3-methylcholanthrene (3-MC, 
initiator) or acetone (negative control) for 72 h, and then incubated in medium with TPA (a promoter) 
for 14 days after washing out of initiator. Finally, the cells were stained and scored for transformed 
colonies. The transformed cells were grown in a disorganized multilayer rather than a monolayer. At 
concentrations of 1, 2, 4 µmol/ml, DDB significantly inhibited transformation of WB-F344 cells in a 
dose dependent manner (inhibitory rates of 10%, 37%, and 47%, respectively). Next, a soft-agar 
colony formation assay was conducted. The cells underwent the procedure described above, but then 
were seeded in soft agar for 28 days instead of being stained. This assay is designed to evaluate a 
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cell's ability to grow unattached to a surface and, therefore, growth in suspended in agar is a sign of 
transformed cells. No colony formation was seen with untreated WB-F344 cells, whereas the cells 
initiated with 3-MC and promoted with TPA developed phenotypic colony formation. The cells 
treated with DDB also formed colonies, but the numbers of colonies were significantly decreased. 
The third experiment involved gap junctional intercellular communication. Gap junctions are 
comprised of proteinaceous, plasma membrane channels that link the interiors of adjacent cells and 
permit cells to directly exchange small (< 1,000 Daltons) molecules and ions. This exchange, termed 
gap junctional intercellular communication (GJIC), is involved in growth regulation, differentiation, 
and apoptosis. Growth controlling factors may pass between cells through the junctions. The loss of 
gap junctions or impairment of their permeability has been observed in many neoplastic cells and 
cells treated with growth promoting carcinogens and other agents. The loss of GJIC appears to be an 
important event in the conversion of a normal cell into a neoplastic one. In the experiment, cells were 
treated with DDB and then TPA. A fluorescent dye permeating gap junctional channel was used to 
detect GJIC. The GJIC of normal WB-F344 cells was good. After exposing the cells to TPA, over 
85% inhibition of GJIC was detected. When the cells were pretreated with DDB, GJIC was recovered 
dose dependently. From the results of these three experiments, it can be concluded that DDB can 
prevent the malignant transformation of WB-F344 cells and restore GJIC. Therefore, DDB has a 
potential chemopreventive effect on hepatocarcinogenesis. 
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Chapter 2 
Introduction of Betulinic Acid on the Researches of Anti-HIV Activity, 
Anticancer Activity, and Cancer Prevention 
 
Natural products are promising source for new drug discovery. Many triterpenoids have been 
shown to have anti-HIV activity and anticancer activity.
1, 2
 A huge breakthrough regarding 
triterpenoids in anti-HIV research occurred when betulinic acid was found to be potent against HIV in 
1994, which led to the discovery and development of a new class of anti-HIV agents, namely, 
maturation inhibitors (MI). 
2.1 Introduction of Betulinic Acid and Bevirimat 
Betulinic acid (BA), 3β-hydroxy-lup-20(29)-en-28-oic acid, a lupane type pentacyclic triterpene, 
was isolated from Betula papyrifera (North American birch tree). Considerable amounts of BA (up to 
2.5%) are available in the outer bark of many terrestrial plant species such as Ancistrocladus 
heyneanus, Diospyros leucomelas, Syzygium formosanum, Tetracera Boliviana, Tryphyllum peltatum, 
and Ziziphus Vulgaris.
3
 Betulin, a structurally close compound and a major constituent of white-
barked birch trees, can be easily converted to BA via Jone’s oxidation followed sodium borohydride 
reduction to give 3α- and 3β-hydroxy products (3:95). Crystallization of the product mixture affords 
BA (3β).4 BA exhibits many pharmacological activities, including antitumor, anti-HIV, antibacterial, 
antimalarial, analgesic, anti-inflammatory, and anthelmintic activities. 
5
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Bevirimat (BVM), also known as PA-457, DSB, and MPC-4326, is 3-O-(3,3-
dimethylsuccinyl)betulinic acid, a derivative of BA. Bevirimat, now in clinical phase II trials, is the 
first member of the novel class of HIV maturation inhibitors. Except for protease inhibitors, most 
FDA-approved drugs target the early steps of the HIV-1 life cycle. However, bevirimat inhibits HIV-
1 maturation, which occurs in the late steps of the HIV-1 life cycle, primarily after virus release from 
infected cells. Bevirimat inhibits HIV-1 maturation by preventing the cleavage of CA-SP1 (p25) gag 
into capsid (p24) and the gag small peptide 1 [SP1 (p2)], which leads to the formation of an immature 
p25 CA protein-SP1 rather than the expected p24 CA protein.  This defective immature p25 CA 
protein-SP1 cannot condense to form the capsid core and results in non-infectious virion progeny. 
The presumed BVM binding site is located near the CA protein-SP1 cleavage site and was found to 
be highly associated with the surrounding gag tertiary structure.
6
 The structures of betulinic acid and 
bevirimat are shown below. 
Figure 2.1. Structures of Betulinic Acid and Bevirimat. 
 
 
2.2 HIV Life Cycle and Possible Drug Targets 
An estimated 34 million people continue to live with acquired immunodeficiency syndrome 
(AIDS) at the end of 2010. Although the number of AIDS-related deaths worldwide has steadily 
decreased to an estimated 1.8 million in 2010 based on WHO reports, new drugs are still needed, 
particularly in less developed countries. Numerous studies have been done to investigate the life cycle 
of HIV in order to identify possible drug targets. The brief HIV life cycle and drug targets are shown 
below. 
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Figure 2.2. HIV Replication Cycle 
 
(From: National institution of Allergy and Infectious Disease (NIAID)) 
HIV entry into host cells, a complicated multi-process associated with the envelope glycoprotein 
(Env), involves three steps. Initially, a conformational change caused by the binding of viral gp120 
with cellular CD4 receptors allows co-receptor binding. Secondly, a further conformational change 
leading to exposure of the hydrophobic fusion domain of gp41 occurs subsequent to by the binding of 
gp120 with CCR5 and/or CXCR4 co-receptor. Finally, a fusion process is mediated by gp41. Once 
the HIV virion is fused together with the cell, the viral capsid is released into the target cell and 
undergoes uncoating to release the HIV RNA genome and various enzymes, including reverse 
transcriptase (RT), integrase (IN), and protease (PR), into cytoplasm. Viral cDNA is reverse 
transcribed by RT using viral genomic RNA as a template. The viral cDNA translocates to the host 
cell nucleus and incorporates into host DNA genome through viral integrase (IN).  
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Following HIV integration, provirus gene expression is tightly controlled via the interplay of viral 
and multiple cellular factors. After viral DNA is transcribed into viral messenger RNA (mRNA), 
mRNA is transported to the cytoplasm and translated into viral proteins by the cell’s machinery. Once 
the Gag polyprotein precursors (Pr55
gag
) and Gag-Pol polyprotein precursors (Pr160
Gag-Pol
) are 
translated, they recruit two copies of viral RNA and assemble with accessory proteins to form the 
core virion near the inner face of the cell membrane. The modified cell membrane containing 
envelope glycoproteins (Env) then surrounds the core particle, and budding begins from the host cell. 
This process leads to the production of immature non-infectious particles. 
During or right after budding, the Gag and Gag-Pol polyproteins are cleaved. This cleavage is 
catalyzed by the third product of the pol gene – protease (PR). PR recognizes and cleaves Gag and 
Gag-Pol polyproteins at several specific sites to produce viral structural proteins [matrix (MA), capsid 
(CA), nucleocapsid (NC) and p6 proteins, as well as three pol products RT, IN and PR itself], which 
leads to the formation of a mature infectious HIV virion that can infect another target cell.  
Based on the knowledge of HIV life cycle, the potential strategies to inhibit HIV are fusion 
inhibition, RT inhibition, IN inhibition, PR inhibition, and maturation inhibition.  
2.3 Progression of Betulinic Acid Modification on Anti-HIV research 
After BA was first found to inhibit HIV-1IIIB replication in 1994, it has been used as a pre-
eminent molecular scaffold in the development of triterpene analogs as anti-HIV drugs.
7
 Systematic 
structural modifications were explored on the A ring C-3 hydroxyl, C-19 isopropenyl group, and C-28 
carboxyl moiety.
8
 However, except for dihydrobetulinic acid (saturation of the C-19 isopropenyl to 
isopropyl group), modifications of C-19 reduced or even eliminated anti-HIV activity. The more 
successful SAR findings are discussed below. 
2.3.1 C-3 position 
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Numerous side chains, including a simple acetyl group
7
, different lengths of acid
9
, and rigid 
acids,
10
 have been connected at the C-3 position via an ester or amide linkage.
11
 Among all side 
chains used, 2,2-dimethylsuccinate is very effective and better than its regio-isomer, 3,3-
dimethylsuccinate.  Only 2,2-methylethylsuccinate resulted in greater activity active than 2,2-
dimethylsuccinate.
7, 9, 12
  
2.3.2 C-28 position
13-16
 
The explored side chains incorporated different chain lengths, amide / ester linkage, and bulky 
amine linkage. Among them, C-28 N-(aminooctanoyl)-4-amino-3-hydroxy-6-methylheptanoic acid 
linkage successfully elevated the activity; however, the mechanism of action of the compound was 
anti-entry rather than anti-maturation as with C-3 modified analogs including bevirimat. 
2.3.3 Bi-functional Modification: C-3 and C-28
14-17
 
Based on the modification studies at C-3 and C-28, Huang et al selected active C-3 side chains 
and C-28 side chains to produce bi-functional derivatives with activity up to 20-fold higher than that 
of bevirimat.
18
 When the bi-functional derivatives were compared with the same C-28 side chain 
modified analogs without a C-3 side chain, the entry inhibition of the bi-functional molecules would 
be lower, implying that C-3 modification might hinder or reduce entry inhibition. However, the bi-
functional derivatives were still more potent than C-28 modified parent compound in terms of total 
inhibition of virus. 
Less research has been performed on A-ring modification for anti-HIV activity. Although an A-
ring dimethylsuccinate side chain is critical for activity, the effects of other A-ring modifications 
remain unclear. In order to explore new BA-based scaffolds, A-ring opened derivatives were designed 
and synthesized, and six ring derivatives were also proposed. 
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2.4 Progression of Betulinic Acid Modification on Anticancer research 
Another important field of BA research is anticancer activity. BA has been tested and proven to 
be active against several cancer cell lines (Table 2.1).
19
  
Table 2.1 In vitro Cytotoxic Effect of Betulinic Acid on Human Cancer Cell Lines. 
Cancer type ED50 (μg/ml) Cancer type ED50 (μg/ml) Cancer type ED50 (μg/ml) 
melanoma 1.1–4.8 glioblastoma 5–16 cervix carcinoma 1.8 
neuroblastoma 2–10 head & neck cancer 8 lung carcinoma 1.5–4.2 
medulloblastoma 3–15 ovarian carcinoma 1.8–4.5 leukemia 2–15 
 
Induction of apoptosis via perturbation of the mitochondrial pathway accounts partly for BA’s 
cytotoxicity (Figure 2.3). In a cell-free system, BA induced loss of mitochondrial membrane potential, 
while in intact cells, BA was shown to trigger cytochrome c in a capase-independent and permeability 
transition pore-dependent manner. Perturbance of mitochondrial permeability plays an important role 
in BA-induced apoptosis leading to caspase activation and apoptotic DNA fragmentation.
20, 21
 Other 
mechanisms were also found for BA’s activity, such as regulation of Bcl-2 family proteins, 
modulation of NF-κB activity, and regulation of angiogenesis. Moreover, BA was identified as potent 
activator of the chymotrypsin-like activity of the proteasome.
22
 Interestingly, neuroblastoma cells 
resistant to doxorubicin-mediated apoptosis still responded to BA treatment, suggesting that BA may 
overcome some forms of drug resistance.
23
Moreover, BA acted collaboratively with different 
cytotoxic agents to suppress tumor growth, including ionic radiation
24
, and chemotherapeutic 
agents.
25, 26
 Thus, BA may be used as a chemosensitizing agent in combination regimens to enhance 
the efficacy of anticancer therapy.  
Four positions, the A-ring, C-3 hydroxyl, C-20 alkene, and C-28 carboxylic acid moieties, have 
served as the targets for most derivatization studies of BA for cytotoxic activity. Based on the 
27 
 
literature results for modification of the C-20 alkene, C-20 position does not appear to be a critical 
site for structural modification. 
2.4.1 C-3 Position (Figure 2.3) 
The 3β-hydroxy moiety represents a readily available position for chemical modifications, including 
acetylation, oxidation to a ketone, and formation of various nitrogen-containing analogs (amines, 
oximes, or carbamates). Oxidation to a ketone increased cytotoxic activity but decreased selectivity.
27
 
An amine (48) or oxime (49) at the C-3 position reduced activity or selectivity.
27
 However, 3-O-
glycosylated derivatives were 8- to 12-fold more potent than BA and showed higher selectivity 
between normal and cancer cells.
28
 Esterification with phthalic acid (50) increased activity in some 
cell lines,
29
 and with 1H-imidazole-1-carboxylic acid (51) significantly elevated cytotoxicity.
30
 In 
summary, modification on the C-3 position resulted in altered potency or selectivity.  
Figure 2.3 Selected C-3 Modified BA derivatives for Anticancer Activity. 
 
2.3.2 Ring A Modification (Figure 2.4) 
In recent studies, modifications at C-2, such as introduction of nitrile, hydroxy, or heterocyclic 
groups, led to increased cytotoxicity. Oxidation of the C-3 hydroxyl coupled with introduction of a C-
2 hydroxyl (54) significantly elevated activity in many cancer cell lines.
31, 32
 Extension of the ring 
system with an indole moiety (56) also led to better activity.
33
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Figure 2.4 Selected BA Derivatives on A-ring Modification. 
 
2.4.3 C-28 Position 
Modification studies at C-28 showed that the C-28 carbonyl group was critical for cytotoxic activity.
8
 
Modification at C-28 was usually combined with modification of other position to achieve better 
activity. Several BA analogs with amino acid side chains at C-28 exhibited melanoma-specific 
cytotoxicity and improved water solubility.
34
 In addition, introduction of polar groups, such as acid, 
amine, or hydroxyl groups, l at the C-28 position could elevate activity.
30
 However, C-28 
glucosidation did not improve activity.
35
  
 
2.5 Progression of Betulinic Acid Modification on Cancer Prevention Research 
BA can inhibit TPA-induced tumors in vivo and ovarian or melanoma xenograft in mice.
36-38
 
Importantly, BA did not exhibit any toxic effect in mice even at a concentration of 500 mg/kg, but 
effectively impeded tumor growth even at 5mg/kg.
39
 Various analogs with fatty acid side chains at C-
3 were synthesized and evaluated for inhibition of TPA-induced tumor activity (Table 2.2).
40
 
Compounds with short fatty acid chains, such as crotonic (60), sorbic (61) or prenyl (62), exhibited 
better cancer preventive activity than BA. In addition, chiral monomethylsuccinyl analogs of BA (57–
59), as well as analogs of ceanothic acid, had comparable activity to BA.
40
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Table 2.2 BA Derivatives for Cancer Preventive Activity 
 
Percentage EBV-EA positive cells 
Compound concentration (mol ratio/TPA
a
) 
Compd R 1000 500 100 10 IC50
b
 
Betulinic 
acid 
-OH 7.9 37.2 75.1 100 403 
Bevirimat 
 
6.1 36.1 74.2 96.5 396 
57 
 
0.0 29.3 70.1 93.1 303 
58 
 
0.0 31.5 71.0 94.2 308 
59 
 
0.0 22.8 71.2 94.7 309 
60 
 
0.0 26.2 66.7 91.6 299 
61 
 
0.0 25.7 65.7 90.2 295 
62 
 
0.0 23.5 62.5 88.7 285 
63 
 
17.0 53.8 83.2 100 546 
64 
 
15.3 50.4 80.1 100 523 
65 
 
10.9 43.3 77.8 97.0 445 
66 
 
12.3 46.1 79.0 100 482 
67 
 
7.3 37.9 75.9 94.8 390 
68 
 
4.8 33.7 72.4 92.5 344 
a
 Concentration of TPA is 32 pmol/ml. 
b
 Concentration of IC50 also presents as mol ratio/TPA. 
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Chapter 3 
Non-toxic Dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-
2,2′-dicarboxylate (DDB) Analogs Chemosensitize Multidrug Resistant 
Cancer Cells to Clinical Anticancer Drugs 
 
3.1 Introduction 
Despite substantial biomedical research on cancer therapy, cancers still remain the leading cause 
of death. Among all factors resulting in the ultimate failure of cancer treatment, chemotherapy 
resistance is a significant player, and multidrug resistance (MDR), cross-resistance to different 
chemical drug classes, occurs in various cancer types. Cellular mechanisms of MDR include 
decreased uptake of chemotherapeutic agents, via expression of vacuolar ATPase (V-ATPase), or 
adaptation of cancer cells to the cytotoxic ability of chemotherapeutic agents, via down-regulation of 
topoisomerase II and over-expression of glutathione S-transferase-π.1-3 Recent studies on cancer stem 
cell-like features are leading to new understanding of cancer resistance.
4
 However, over-expression of 
drug efflux transporters, such as P-glycoprotein (P-gp) and MDR-associated protein (MRP), is still 
believe to be the primary cause leading to multidrug resistance.
5
 In order to surmount MDR, great 
efforts have been put into developing clinically usable chemosensitizing agents, categorized as either 
apoptosis modulators
6, 7
 or MDR modulators, also known as P-gp inhibitors.
8
 Verapamil (VRP) and 
cyclosporine A, two first-generation chemosensitizers, were precluded from clinical use due to 
significant toxicity, but are used in experiments as positive controls. Second- and third-generation 
chemosensitizers were developed subsequently; however, unsatisfactory toxicity and pharmacokinetic 
complications still impeded drug candidate development. Thus, the discovery of safe and effective 
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MDR modulators is still attractive and greatly needed to overcome the MDR issue in the field of 
cancer chemotherapy.  
Schisandrin B (Figure 3.1), the most abundant dibenzocyclooctadiene lignan from Schisandra 
chinensis, was found to inhibit P-gp/MDR1 and MRP1/ABCC1.
9,10
 Structurally similar lignans, 
schisandrin A, schisandrol A, and schisantherins A and B, also chemosensitized various anticancer 
drugs, including vincristine (VCR), daunorubicin, and etoposide, in human promyelocytic leukemia 
cell lines with over-expressed MRP1/ABCC1.
11
 Dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene 
dioxybiphenyl-2,2′-dicarboxylate (DDB, 1, Figure 3.1), which was discovered as a synthetic 
intermediate derivative of schisandrin C,
12
 shares the biphenyl partial structure of 
dibenzocyclooctadiene lignans. DDB (1) exhibited multidrug resistant reversal ability in vitro and in 
vivo and DDB’s analog, bicyclol also shown chemoreversal activity mentioned in chapter 1.13,14 
However, a very high concentration (50 µM) was required for their effective reversal action. DDB’s 
low toxic feature makes DDB analogs highly attractive MDR reversal agents. Although DDB and 
bicyclol have high potentials as MDR reversal agents and various DDB analogs have been prepared, 
their MDR reversal abilities and structure activity relationship (SAR) correlations have been not 
investigated. To explore more potent non-toxic MDR reversal analogs with lower effective dosing 
and to study SAR, we designed and synthesized additional DDB analogs. Herein, we report the 
chemosensitizing effects of newly synthesized DDB analogs. 
 
 
 
 
 
36 
 
Figure 3.1 Structures of DDB, Bicyclol, and Dibenzocyclooctadiene Lignans 
 
3.2 Design and Synthesis 
The P-gp contains a large drug-binding pocket with a volume of around 6000Å
3
.
15
 The pocket 
includes predominantly hydrophobic and aromatic residues in its upper half and more polar and 
charged residues in its lower half. Thus, because of similarity, hydrophobic substrates would bind to 
the hydrophobic residues, and aromatic substrates would overlap with the π-orbitals of aromatic 
residues in the binding pocket.  Further evaluation of the chemical structures of various known P-gp 
inhibitors identified common features, including high hydrophobicity, two or more aromatic rings, a 
methoxy group on the aromatic ring, and one or two protonatable nitrogens.
16
 Among the above 
mentioned features, DDB already possesses two aromatic rings with a methoxy group on each. 
Because bicyclol bears a primary alcohol at the C-2′ position, we selected the 2,2′-bis-hydroxymethyl 
analog 69
 
as a base scaffold to design various esters 70–95 (Scheme 3.1) and define substituent 
effects at the C2 and C2′ positions. The ester groups (R in Scheme 3.1) were selected by considering 
size, hydrophobicity, and electron density, which might affect the binding affinity to P-gp. The 
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diverse set included acyclic, cyclic, unsaturated aliphatic groups, aromatic groups, and polar groups, 
which could be transformed into water-soluble salts, if necessary. Esterifications of 69 were 
performed by treatment with the appropriate acid (RCO2H), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDCI), and 4-dimethylaminopyridine (DMAP) to produce 70, 74–
79, 82–84, and 89, as well as by treatment with the related acid chloride (RCOCl) and Et3N to give 
71–73, 80–81, 86–88, and 90–95 (Scheme 3.1).     
Halogenated DDB analogs were also designed to explore their effects (Scheme 3.2). 3,3′-Dibromo-
DDB (96) was previously synthesized.
17
 Iodination of 1 was achieved by treatment with silver 
trifluoacetate and iodine to provide 97.
18
 The diester groups of 96 were reduced with 
diisobutylaluminium hydride (DIBAL) to afford bis-hydroxymethyl biphenyl 98 in good yield. A 
bulky group or aromatic ring is a common feature of several MDR modulators as mentioned above. 
Therefore, the esters 99 and 100 were also synthesized by esterification of 98 with butyric and 
benzoic acids, respectively, in the presence of EDCI and DMAP. Hydrolysis of dimethyl ester 96 
under basic conditions resulted in dicarboxylic acid 101. Reflux of 101 in Ac2O gave anhydrous 
analog 102, followed by asymmetric cleavage of carbonyl anhydrous bridge with NaBH4 resulted in 
di-Br bicyclol analog 103.
19
 All synthesized analogs were prepared as racemic mixtures. 
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Cmpd 
R  
 
Aliphatic 
Acyclic Group (I) 
 
 
 
Cmpd 
R  
 
Aliphatic 
Cyclic Group (II) 
 
 
 
Cmpd 
R 
Aromatic Group 
(V) 
 
70 Me 80 
 
86 R' = H 
71 Et 81 
 
87 R' = 4-Me 
72 iPr   88 R' = 4-OMe 
73 tBu  
Unsaturated 
Group (III) 
89 R' = 3,4-diOMe 
74 Pr 82 
 
90 
R' = 3,4,5-
triOMe 
75 sec-Bu  83 
 
91 R' = NO2 
76 iBu 84 
 
92 R' = CN 
77 Bu   93 
R' = 3,4-
methylenedioxy 
78 -CH(CH3)CH2CH2CH3  Polar Group (IV) 94 
 
79 -(CH2)10CH3 85 -CH2CH2CO2H 95 
 
 
39 
 
Scheme 3.2. Syntheses of Dihalogenated DDB Analogs 
 
3.3 Results and Discussion 
Evaluation of cytotoxicity and preliminary MDR reversal activity screening.  
All synthesized compounds were initially evaluated in a cytotoxic activity assay using four tumor 
cell lines, A549 (lung cancer), DU145 (prostate cancer), KB (epidermoid carcinoma of the 
nasopharynx) and a resistant sub-line, KBvin (over-expression of P-gp selected using increasing 
concentrations of vincristine). Although compounds 95 and 99 were slightly cytotoxic, the other 
compounds did not exhibit significant cytotoxicity (Table 3.1), which implied low toxicity of these 
analogs. 
For evaluating chemosensitizing activity, KB and KBvin cells were co-treated with test 
compound at 10 µM and the anticancer drug paclitaxel (TAX), as well as with test compound alone at 
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the same concentration (Figure 3.2). As shown in Figure 3.2-B, DDB (1) and diol 69 did not exhibit 
an MDR reversal effect at a concentration of 10 µM in KBvin cells. However, many of the analogs 
with aliphatic ester substituents (I and II in Figure 3.2) did show potent activity, although acetate 70 
(R = methyl) and dodecanoate 79 (R = undecanyl) were inactive, and 2-methylhexanoate 78 (R = 2-
methybutyl) was only moderately active. The screening results implied a rough SAR; at least a two 
carbon linear ester chain (R = ethyl) was necessary for chemosensitizing activity, but a long chain (R 
> approximately five carbons), led to reduced or no activity. Isobutyrate (R = isopropyl) 72 and 
pivalate (R = tert-butyl) 73 resulted in the most significant chemosensitization (cell survival rate of 
13–14%) among all saturated Group I and II compounds, and the unsaturated 3-methylbut-2-enoate 
(prenyl-like substituent) 83 in the Group III compounds further increased the effect, resulting in a cell 
survival rate of only 5%. Among the Group IV compounds with polar ester substituents, succinate 85 
(R = CH2CH2COOH) was inactive, while compounds with phenyl or pyridinyl aromatic rings showed 
potent reversal ability, unless an electron-withdrawing group, such as nitro and cyano, was present on 
the aromatic ring. Notably, benzoate 86 and p-methoxybenzoate 88 led to less than 1% cell survival 
rate. From these findings, we speculated that a decrease in electron density on the aromatic ring 
affected the overlap of the compound with the π–orbitals of aromatic residues in the P-gp drug-
binding pocket. Quinoline derivative 95 exhibited cytotoxicity against both KB and KBvin cells. 3,3′-
Dihalogenated DDB analogs with different 2,2′-functional groups did not show potent reversal 
activity, except pentanoate 99 and benzoate 100, but 99 was cytotoxic to KBvin cells (Table 3.1). 
While a 2,2′-methylester group [-CH2OC(O)R] appeared to be critical for reversal ability, 3,3′-
halogenation reduced the potency (compare 100 with 86). 
Because the presumptive drug-binding pocket is composed of mostly hydrophobic and aromatic 
residues,
15
 it is possible that hydrophobicity of DDB analogs could influence their MDR reversal 
activity. Table 3.2 shows the Clog P values of synthesized compounds. Although a few exceptions 
were present, the chemosensitizing effects of compounds were moderately correlated with their Clog 
P values. Active compounds had Clog P values of 4–8; those with Clog P lower than 4 tended to lose 
41 
 
chemosensitizing activity. The Clog P values of 73, 83, and 90, which as described below were 
significantly active, were between 4.8 and 6.2, which is close to that of VRP. This fact implied that 
hydrophobicity is an important parameter, although other factors could also affect potency.  
From these results, compounds 71–78, 80–84, and 86–91 were selected for further investigation; 
compounds with weaker reversal ability (1, 69–70, 79, 85, 91–94, 96–98, and 102–103) as well as 
inherent cytotoxicity (95 and 99) were eliminated from further testing. 
Table 3.1. Cytotoxicity of DDB Analogs 
Compd 
GI50 (µM)
a
 
A549 DU145 KB KBvin 
1, 69-72 >100 >100 >100 >100 
73 98 >100 >100 >100 
74-94 >100 >100 >100 >100 
95 45 >100 88 71 
96-98 >100 >100 >100 >100 
99 13 19 24 19 
100-103 >100 >100 >100 >100 
TAX
b
 7.0 nM 2.9 nM 1.2 nM 1290.9 nM 
a
 Antiproliferative activity as GI50 values for each cell line, the concentration of compound that caused 
50% reduction in absorbance at 562 nm relative to untreated cells using the sulforhodamine B assay. 
Human lung carcinoma (A549), prostate cancer (DU145), epidermoid carcinoma of the nasopharynx (KB), 
and MDR expressing P-glycoprotein (KB-VIN). All compounds, besides 95 and 89, exhibited no 
cytotoxicity. 
b
Paclitaxel  
 
Table 3.2. CLogP Values of Synthesized Compounds 
Compd CLog P
a
 Compd CLog P Compd CLog P Compd CLog P 
1 4.27 77 6.15 86 6.93 95 6.21 
69 1.26 78 6.77 87 7.93 96 4.68 
70 2.98 79 N/A 88 7.28 97 5.02 
71 4.03 80 5.92 89 6.69 98 2.60 
72 4.65 81 7.04 90 5.93 99 7.49 
73 5.45 82 5.24 91 6.42 100 8.27 
74 5.09 83 6.04 92 5.80 101 1.96 
75 5.71 84 6.51 93 7.31 102 5.34 
76 5.89 85 2.40 94 6.11 103 2.28 
      VRP 4.58 
a
 CLogP was calculated by ChemDraw Ultra Version 12.0 
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 Figure 3.2. Screening of Reversal Abilities against KB (A) and KBvin (B) 
Note: 
a 
Concentration of compounds: 10 µM, 
b
 Survival rate (%) was measured by SRB method using 
KB and KBvin cells in the presence (+) or absence (-) of paclitaxel(TAX). Compounds with survival 
rates below 20 % were considered very potent and moved to further experiments. 
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Chemoreversal ability of DDB analogs with TAX, VCR, and doxorubicin (DOX).  
A quantitative evaluation of the reversal ability of DDB analogs 71–78, 80–84, and 86–90 was 
performed using MDR KBvin cells with various concentrations of TAX, VCR, and DOX, which are 
clinically used and known as significant P-gp substrates (Table 3.3). The IC50 value of cancer drug in 
the presence of test compound at 10 µM concentration was calculated and fold reversal was 
determined by dividing the IC50 of anticancer drug alone by the IC50 of anticancer drug plus DDB 
analog. For chemoreversal ability against TAX resistance, compounds 76, 82, 83, 86, and 90 were 3–
10 times more potent than the positive control VRP. Especially, 83, with a prenyl-like ester 
substituent, and 90, with a trimethoxybenzoate substituent, effectively reversed the sensitivity of TAX 
in KBvin cells by 326- and 222-fold, respectively. Most of the tested analogs, along with VRP, 
showed greater reversal against VCR resistance compared with TAX resistance. The reversal effects 
of compounds 73, 77, 80–83, 89, and 90 against VCR were significantly better than that of VRP. 
Notably, 83 and 90 showed a 560-fold reversal effect, 5.1 times greater than that of VRP. The 
following SAR correlations were proposed based on the chemosensitizing effects against TAX and 
VCR. In compounds with aliphatic esters, unsaturated Group III compounds 82 and 83 were generally 
more potent than saturated group I and II compounds. Compounds 82 and 83 displayed greater 
chemoreversal ability than 74 and 76, which contain structurally related saturated groups. In the case 
of compounds with aromatic esters (Group V), an electron donating group, such as methyl and 
methoxy, at the para-position reduced the reversal ability, while additional methoxy groups at the 
meta-position enhanced the ability. The following rank order of potency was seen: 3,4,5-tri-OMe (90) 
> 3,4-di-OMe (89) > H (86) > 4-Me (87) ≈ 4-OMe (88). Different SAR correlations were found 
between TAX and VCR within the saturated aliphatic group. Cyclic aliphatic side chains (Group II, 
80–81) were more effective than non-cyclic aliphatic side chains (Group I, 71–78) in the case of VCR 
resistance, while a difference was not present for TAX resistance. Within the tested aliphatic acyclic 
Group I compounds (71–78), 2-methylbutyrate (R = iso-butyl) 76 was most potent for TAX, while 
pivalate (R = tert-butyl) 73 and petanoate (R = n-butyl) 77 were most potent for VCR. In addition, 77 
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exhibited greater activity than the related unsaturated analog 84 against VCR resistance. All of the 
tested compounds were less effective at reversing DOX resistance compared with TAX and VCR 
resistance. This phenomenon might be correlated with the location of the efflux pump, either on the 
cell membrane or on the nuclear membrane, because both TAX and VCR act by binding tubulin, 
while DOX interacts with DNA by intercalation.
20
 However, compounds 73, 75, 78–81, and 87–90 
still showed greater reversal effects than VRP for DOX chemosensitivity in MDR cells. Pivalate 73, 
with a bulky and short aliphatic ester chain, reversed the activity most effectively, exhibiting five-fold 
more sensitivity than VRP. SAR against DOX was slightly different than that against VCR. 
Compounds 73, 75, 78, 80, and 81 with a branched substituent at the ester α-position showed 
significant MDR reversal activity. Benzoates with an electron donating group, such as para-methyl 
(87) and –methoxy (88), had little effect. Although an additional methoxy group at the meta-position 
increased the ability, no difference was found between trimethoxy 90 and dimethoxy 89. The effects 
of substituent on phenyl ring resulted in the following order of potency: 3,4-di-OMe (89)≈3,4,5-tri-
OMe (90) > H (86) ≈4-Me (87) ≈4-OMe (88). In conclusion, analogs 83 and 90 showed the most 
significant TAX and VCR cytotoxic reversal ability, while analog 73 exhibited the most potent DOX 
cytotoxic reversal ability. 
Based on the above results, compounds 73 and 90 were selected for a dose-response analysis of 
chemosensitization efficacy. Because their ability to induce full cancer drug sensitivity is unclear, 
dose-response curves of growth inhibition by TAX (A), VCR (B), and DOX (C) in the presence of 73, 
90, or VRP were compared to parent cell drug sensitivity (Figure 3.3). After treatment with 73, 90, or 
VRP at 10 µM, the growth inhibition curves for the three anticancer drugs in KBvin cells shifted 
toward and were similar to those against the parental KB cell line. This result shows that 73 and 90 
can completely inhibit cellular P-gp and thereby confer full sensitivity to the tested clinically relevant 
anticancer drugs.  
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Table 3.3. Reversal Effects with Paclitaxel (TAX), Vincristine (VCR), and Doxorubicin (DOX) 
in KBvin  
Group Cmpd
a
 
GI50 of TAX 
(nM)
b
 
Fold
c
 
GI50 of VCR 
(nM) 
Fold 
GI50 of DOX 
(nM) 
Fold 
 TAX 976.8  - 2520.7 - 1942.3 - 
I 
71 82.93 12 80.96 31 507.5 4 
72 46.52 21 41.42 61 284.0 7 
73 26.15 37 7.22 349 42.6 46 
74 30.50 32 50.81 50 510.9 4 
75 37.06 26 35.92 70 93.9 21 
76 8.72 112 31.75 79 339.7 6 
77 40.74 24 15.65 161 221.5 9 
78 39.11 25 47.31 53 61.9 31 
II 
80 48.65 20 8.14 310 86.3 23 
81 39.89 24 10.55 239 65.8 30 
III 
82 9.55 102 10.98 230 547.8 4 
83 2.99 326 4.50 560 291.5 7 
84 47.45 21 46.53 54 573.9 3 
V 
86 7.65 167 20.21 101 157.7 9 
87 46.82 27 39.61 51 130.8 11 
88 47.23 27 40.53 50 131.4 11 
89 14.25 89 10.10 202 68.80 21 
90 4.41 222 4.45 566 84.2 23 
 VRP 31.87 31 23.04 109 219 9 
a 
Concentration of compound: 10 µM, 
b
SD was shown in Supporting Information, 
c
 The reversal fold 
values were calculated as: Reversal fold = IC50 (anticancer drug alone) / IC50 (anticancer drug + test 
compound). 
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Figure 3.3. Dose-response of growth inhibition of 73 and 90 together with Paclitaxel, Vincristine 
and Doxorubicin against KB and KBvin. KBvin (●) and KB (○) cells were treated with various 
concentrations of TAX (A), VCR (B), or DOX (C) alone or together with 10 μM of 73 (▲), 90 (■), 
or verapamil (◆). The incubation period was 72 hours before the cell viability was measured by SRB 
method as described in Materials and Methods. Compounds 73 and 90 were able to elevate the 
sensitivity of KBvin to the anticancer drug (TAX, VCR, and DOX) to a level similar to or lower than 
that of KB. 
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Dose-response effect of compounds 73 and 90 on sensitization of KBvin to TAX.  
To evaluate the reversal activity of 73 and 90 in a dose-response manner, KBvin cells were 
cultured with non-toxic concentration of TAX (100 nM) in the presence of various concentrations of 
compounds (Figure 3.4). As we expected, compounds 73 and 90 exhibited reversal activity in a dose 
dependent manner. Although median effective concentration (EC50) value of 73 (2.81 µM) was 
similar to that of VRP (2.71 µM), 90 (1.87 µM) was more potent than VRP. These results 
demonstrate that 90 is more effective than VRP in chemosensitizing the MDR cells to TAX. 
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Figure 3.4. Dose-response effect of compounds 73 and 90 on sensitization of KBvin to TAX. 
Multidrug resistant KBvin cells were treated with various concentrations of compounds 73 or 90 in 
the presence of 100 nM TAX, an absolutely non-toxic concentration for KBvin. Data are expressed as 
mean ± SD of three independent experiments.  Calculated median effective concentration (EC50) of 
compounds 73, 90, or VRP was 2.81 µM, 1.87 µM or 2.71 µM, respectively.    
 
The effect of DDB analogs on P-gp function in KBvin cells.  
To confirm our hypothesis that DDB analogs inhibit efflux activity of P-gp resulting in elevated 
concentration of anticancer drugs in MDR cells, the effect of compounds 73 and 90 on P-gp function 
in KBvin cells using Calcein-AM as a fluorogenic P-gp substrate was investigated (Figure 3.5). Dose 
dependent intracellular accumulation of Calcein was observed in the presence of compounds. 
Although 73 was slightly less potent than VRP, 90 displayed two-fold more potent than VRP, 
especially at a concentration of EC50 value (1.87 µM) for TAX. Therefore, these results clearly 
indicated that DDB analogs, especially 90, are effective P-gp inhibitors.  
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Figure 3.5. Effect of compounds on P-gp function in KBvin cells. KBvin cells were pre-treated 
with compounds followed by addition of calcein-AM. The cellular accumulation of calcein is 
represented by the relative fluorescent unit (104 RFU). Cellular accumulation of calcein 
demonstrates inhibition of efflux activity of P-gp.  
 
 
   To demonstrate the effective efflux inhibition of anticancer drugs, direct measurement of cellular 
accumulation of DOX in KBvin cells was studied as the intensity of intrinsic fluorescence of DOX 
(Figure 3.6). KBvin cells were pre-treated with compounds followed by addition of DOX. 
Intracellular accumulation of DOX was measured as the fluorescence intensity and standardized as 
fold ratio. All DDB analogs induced DOX accumulation in KBvin cells at 1.2- to 2.4-fold. The 
cellular accumulation of DOX by DDB analogs was consistent with sensitization of KBvin cells to 
DOX. Thus, these data further support that DDB-derived chemosensitizers function as P-gp inhibitors 
resulting in cellular accumulation of anticancer drugs.     
   Further screening studies demonstrated that DDB analogs sensitized NIH3T3-MDR cells (murine 
fibroblast NIH3T3 cells with overexpressing human P-gp protein) to TAX and VCR (unpublished 
data). These results also support our conclusion that DDB analogs interfere with drug efflux function 
of P-gp. 
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Figure 3.6. Recovered Doxorubicin Accumulation in DDB Analog-treated Drug Resistant 
KBvin cells. Cells were incubated in DOX medium for 3 h in the presence of 10 µM DDB analogs to 
measure DOX accumulation. DDB analogs were able to recover DOX accumulation level to the same 
or greater extent than VRP. Data represent as mean ± SD, n= 3. VRP and cyclosporine (CsA) were 
used as positive controls.  
 
3.4 Conclusions 
Multidrug resistance is still a serious barrier to successful cancer treatment. Among the possible 
reasons for multidrug resistance, the top cause is the reduction in the concentration of the anticancer 
drug caused by the P-gp and/or MRP drug efflux pump. Effective P-gp modulators are still 
unavailable for clinical use, due partly to the toxicity of the currently available compounds. We 
selected DDB, a clinically used hepatoprotective compound, as a lead, and 33 new DDB analogs were 
newly designed and synthesized. All synthesized analogs were evaluated for MDR chemosensitizing 
effects of the clinical cancer drug TAX, and selected compounds were also tested for effects on the 
drugs VCR and DOX. Most of the 2,2′-methylester DDB analogs exhibited improved chemoreversal 
action compared with the parent compound. The SAR findings are summarized in Figure 3.5. 
Insertion of halogen at the 3-position reduced the reversal ability, while. bulky groups, such as 
pivalate, 2-methylbutanoate, cyclic aliphatic, and trimethoxyphenyl, in the ester side chain at the 2-
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position, tended to enhance the reversal ability of DDB analogs. Among all tested compounds, DDB 
derivatives 83 and 90 were 5–10 times more effective than VRP for enhancing TAX and VCR 
activity, and analog 73 was five times more effective than VRP for enhancing DOX activity. 
Importantly, active DDB analogs displayed no cytotoxicity at 10-fold higher concentration, 
suggesting that they are significant lead compounds for further clinical development to overcome 
multidrug resistance. DOX accumulation inside KBvin cells upon treatment with DDB analogs 
confirmed that the mechanism of reversal ability is due, at least partly, to drug efflux pump inhibition. 
Preliminary mechanism of action studies showed that the most promising DDB analogs impeded the 
efflux ability of resistant cancer cells and thereby facilitated accumulation of the cytotoxic drug DOX.  
To conclude, DDB was identified as a new scaffold for chemosensitizer drug development, and 
newly synthesized non-toxic DDB analogs were discovered. Detailed mechanism of action studies are 
ongoing to completely elucidate the mechanism of chemoreversal by DDB analogs. 
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3.5 Materials and Methods 
Chemistry 
General. 
1
H NMR (400 MHz) spectra were measured on a Varian Inova spectrometer with TMS as 
the internal standard. Mass spectra were measured on a Shimazu LCMS-IT-TOF. All reactions were 
monitored by thin-layer chromatography (TLC) on aluminum sheets (silica gel 60 F254 plate, 20 × 20, 
Merk). Melting points were recorded on a Fisher Johns melting apparatus without correction. 
Medium-pressure column chromatography was used in Biotage Flash and Isco companion systems 
with silica 40 µM columns from Grace Inc. All final compounds are >95 % pure based on HPLC. 
Anhydrous solvents were purchased from commercial suppliers. 
General synthetic procedure for compounds 70, 74-79, 82-84, and 89 
To a solution of 69 in CH2Cl2, an appropriate carboxylic acid (5 equiv mol), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (5 equiv mol) and 4-
(dimethylamino)pyridine (1 equiv mol) were added and stirred overnight. The reaction mixture was 
then applied directly to preparative TLC (hexane-EtOAc) without work-up. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) diacetate (70). 
Yield 85%; colorless oil; 
1
H NMR (CDCl3)  6.69 (s, 2H), 5.97 (s, 2H), 5.95 (s, 2H), 4.85 (s, 4H), 
3.95 (s, 6H), 1.99 (s, 6H); HRMS calcd for C22H22NaO10 (M+Na)
+
 469.1111, found 469.1116. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) dibutyrate (74). 
Yield 97%; colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 1H), 5.96 (d, J = 1.4 Hz, 2H), 5.95 (d, J = 1.4 
Hz, 2H) 4.86 (s, 4H), 3.93 (s, 6H), 2.22 (t, J = 7.2, 4H), 1.59 (sex, J = 7.2 Hz, 4H), 0.90 (t, J = 7.2 Hz, 
6H); HRMS calcd for C26H30NaO10 (M+ Na)
+
 525.1737, found 525.1759. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(2-
methylbutanoate) (75). Yield 83%; colorless oil ; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.97 (s, 2H), 5.95 
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(s, 2H), 4.91–4.82 (m, 4H), 3.93 (s, 6H), 2.32 (sex, J = 6 Hz, 2H), 1.67–1.56(m, 2H), 1.48–1.36 (m, 
2H), 1.09 (d, J = 7.2 Hz, 3H), 1.07 (d, J = 7.2 Hz, 3H), 0.84 (dd, J = 7.4, 14.6 Hz, 6H); HRMS calcd 
for C28H34NaO10 (M + Na)
+
 553.2050, found 553.2063. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(3-
methylbutanoate) (76). Yield 91%; colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.96 (s, 2H), 5.95 
(s, 2H), 4.86 (s, 4H), 3.93 (s, 6H), 2.12 (d, J = 6.4 Hz, 4H), 2.03 (m, 2H), 0.90 (dd, J = 2.8, 6.6 Hz, 
12H); HRMS calcd for C28H34NaO10 (M + Na)
+
 553.2050, found 553.2063. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) dipentanoate (77). 
Yield 99%; colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.96 (d, J = 1.5 Hz, 2H), 5.94 (d, J = 1.5 
Hz, 2H), 4.85 (s, 4H), 3.93 (s, 6H), 2.23 (t, J = 7.6 Hz, 4H), 1.54 (pent, J = 7.6 Hz, 4H), 1.29 (sex, J = 
7.6 Hz, 4H), 0.88 (t, J = 7.6 Hz, 6H); HRMS calcd for C28H34NaO10 (M + Na)
+
 553.2050, found 
553.2067. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(2-
methylpentanoate) (78). Yield 85%; colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.97 (s, 2H), 
5.95 (s, 2H) 4.91–4.81 (m, 4H), 3.93 (s, 6H), 2.37 (dd, J = 7.2, 14 Hz, 2H), 1.64–1.13 (m, 8H), 1.09 
(d, J = 7 Hz, 3H), 1.07 (d, J = 7 Hz, 3H), 0.86 (t, J = 6.8 Hz, 6H); HRMS calcd for C30H38NaO10 (M + 
Na)
+
 609.2676, found 609.2688. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) didodecanoate (79). 
Yield 88%; colorless oil; 
1
H NMR (CDCl3, 400 MHz)  6.68 (s, 2H), 5.96 (d, J = 1.5 Hz, 2H), 5.94 (d, 
J = 1.5 Hz, 2H), 4.85 (s, 4H), 3.93 (s, 6H), 2.22 (t, J= Hz, 4H), 1.57–1.19 (m), 0.87 (t, J = 6.8 Hz, 
6H); HRMS calcd for C42H62NaO10 (M + Na)
+
 749.4247, found 749.4225. 
(2E,2’E)-(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(but-2-
enoate) (82). Yield 8%; colorless oil; 
1
H NMR (CDCl3)  6.96–6.87 (m), 6.7 (s, 2H), 5.94 (s, 4H), 
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5.78 (d, J= 15.6 Hz, 2H), 4.94 (d, J = 12.4 Hz, 2H), 4.85 (d, J = 12.4 Hz, 2H), 3.93 (s, 6H), 1.85 (d, J 
= 6.8 Hz, 6H); HRMS calcd for C26H26NaO10 (M + Na)
+
 521.1424, found 521.1449. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(3-methylbut-2-
enoate) (83). Yield 51%; colorless oil; 
1
H NMR (CDCl3)  6.70 (s, 2H), 5.94 (d, J = 1.5 Hz, 2H), 
5.93 (d, J = 1.5 Hz, 2H), 5.62 (s, 2H), 4.95 (d, J = 12.5 Hz, 2H), 4.82 (d, J = 12.5 Hz, 2H), 3.93 (s, 
6H), 2.12 (s, 6H), 1.86 (s, 6H); HRMS calcd for C28H30NaO10 (M + Na)
+
 549.1737, found 549.1761. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(hexa-2,4-
dienoate) (84). Yield 55%; colorless oil; 
1
H NMR (CDCl3)  7.19 (d, J = 9.8 Hz, 1H), 7.15 (d, J = 9.8 
Hz, 1H), 6.70 (s, 2H), 6.18–6.08 (m, 4H), 5.93 (d, J = 1.5 Hz, 4H), 5.71 (s, 1H), 5.68 (s, 1H), 4.96 (d, 
J = 12.3 Hz, 4H), 4.87 (d, J = 12.3 Hz, 4H), 3.93 (s, 6H), 1.83 (d, J= 5.2 Hz, 6H); HRMS calcd for 
C30H30NaO10 (M + Na)
+
 573.1737, found 573.1746. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(3,4-
dimethoxybenzoate) (89). Yield 90%; colorless oil; 
1
H NMR (CDCl3)  7.55 (dd, J = 2, 8.4 Hz, 2H), 
7.43 (d, J = 2 Hz, 2H), 6.78 (d, J = 8.4 Hz, 2H), 6.76 (s, 2H), 5.91 (s, 2H), 5.81 (s, 2H), 5.14 (d, J = 
12.4 Hz, 2H), 5.04 (d, J = 12.4 Hz, 2H), 3.93 (s, 6H), 3.89 (s, 6H), 3.88 (s, 6H); HRMS calcd for 
C36H34NaO14 (M + Na)
+
 713.1846, found 713.1839. 
General procedure for compound 71-73, 80-81, 86-88, and 90-95 
To a flask with anhydrous dichloromethane, compound 69 and triethylamine (5-10 equiv mol) were 
added first and then the appropriate acyl chloride (2.2 equiv mol) was added at 0 C under nitrogen. 
The reaction mixture was warmed gradually to room temperature and stirred for 1–3 h. After the 
reaction was completed, water and saturated sodium carbonate solution were added and the reaction 
mixture was extracted with dichloromethane, dried over sodium sulfate, and concentrated. Further 
purification was done by combiflash (hexane-EtOAc gradient). 
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(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) dipropionate (71). 
Yield 99%; colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.95 (d, J = 6.5 Hz, 4H), 4.85 (s, 4H), 3.93 
(s, 6H), 2.26 (q, J = 7.2 Hz, 4H), 1.08 (t, J = 7.6 Hz, 6H); HRMS calcd for C24H27O10 (M + H)
+
 
497.1424, found 497.1432. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(2-
methylpropanoate) (72). Yield 83%; colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.96 (dd, J = 9.2 
Hz, 4H), 4.88 (d, J = 12.6 Hz, 2H), 4.84 (d, J = 12.6 Hz, 2H), 3.93 (s, 6H), 2.49 (sept, J = 7.2 Hz, 2H), 
1.11 (t, J = 7.2 Hz, 12H); HRMS calcd for C26H30NaO10 (M + Na)
+
 525.1737, found 525.1754. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(2,2-
dimethylpropanoate) (73). Yield 82%; colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.96 (d, J = 
13.8 Hz, 4H), 4.91 (d, J = 12.8 Hz, 2H), 4.82 (d, J = 12.8 Hz, 2H), 3.93 (s, 6H), 1.15 (s, 18H); HRMS 
calcd for C28H34NaO10 (M + Na)
+
 553.2050, found 553.2054. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) 
dicyclopentanecarboxylate (80). Yield 99 %; colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.95 (d, 
J = 7.9 Hz, 4H), 4.88 (d, J = 12.6 Hz, 2H ), 4.84 (d, J = 12.6 Hz, 2H), 3.93 (s, 6H), 2.71–2.65 (m, 2H), 
1.88–1.52 (m, 16H); HRMS calcd for C30H34NaO10 (M + Na)
+
 577.2050, found 577.2052. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) 
dicyclohexanecarboxylate (81). Yield 99%; colorless oil; 
1
H NMR (CDCl3)  6.67 (s, 2H), 5.95 (d, J 
= 7.6 Hz, 4H), 4.87 (d, J = 12.6 Hz, 2H), 4.83 (d, J= 12.6 Hz, 2H), 3.93 (s, 6H), 2.27–2.20 (m, 2H), 
1.95–1.13 (m, 20H); HRMS calcd for C32H38NaO10 (M + Na)
+
 605.2363, found 605.2387. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) dibenzoate (86). 
Yield 59%; colorless amorphous; 
1
H NMR (CDCl3)  7.94–7.92 (m, 4H), 7.52–7.47 (m, 2H), 7.38–
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7.34 (m, 4H), 6.76 (s, 2H), 5.90 (s, 2H), 5.79 (s, 2H), 5.15 (d, J = 12.3 Hz, 2H), 5.06 (d, J = 12.3 Hz, 
2H), 3.93 (s, 6H); HRMS calcd for C32H26NaO10 (M + Na)
+
 593.1424, found 593.1452. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(4-
methylbenzoate) (87). Yield 34%; colorless amorphous; 
1
H NMR (CDCl3)  7.81 (d, J = 8.0 Hz, 4H), 
7.15 (d, J = 8.0 Hz, 4H), 6.75 (s, 2H), 5.91 (s, 2H), 5.81 (s, 2H), 5.12 (d, J = 12.5 Hz, 2H), 5.04 (d, J 
= 12.5 Hz, 2H), 3.92 (s, 6H), 2.35 (s, 6H) ; HRMS calcd for C34H30NaO10 (M + Na)
+
 621.1737, found 
621.1761. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(4-
methoxybenzoate) (88). Yield 30%; colorless amorphous; 
1
H NMR (CDCl3)  7.90–7.86 (m, 4H), 
6.85–6.81 (m, 4H), 6.75 (s, 2H), 5.91 (s, 2H), 5.82 (s, 2H), 5.12 (d, J = 12.3 Hz, 2H), 5.03 (d, J = 12.3 
Hz, 2H), 3.93 (s, 6H), 3.80 (s, 6H); HRMS calcd for C34H30NaO12 (M + Na)
+
 653.1635, found 
653.1615. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(2,3,4-
trimethoxybenzoate) (90). Yield 98%; colorless amorphous; 
1
H NMR (CDCl3)  7.18 (s, 4H), 6.73 
(s, 2H), 5.90 (s, 2H), 5.77 (s, 2H), 5.16 (d, J = 12.3 Hz, 2H), 5.04 (d, J = 12.3 Hz, 2H), 3.92 (s, 6H), 
3.87 (s, 6H), 3.86 (s, 12H); HRMS calcd for C38H39O16  (M + H)
+
 773.2058, found 773.2050. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(4-
nitrobenzoate) (91). Yield 52%; colorless amorphous; 
1
H NMR (CDCl3)  8.22–8.19 (m, 4H), 8.09–
8.06 (m, 4H), 6.75 (s, 2H), 5.92 (s, 2H), 5.85 (s, 2H), 5.18 (d, J = 12.4 Hz, 2H), 5.12 (d, J = 12.4 Hz, 
2H), 3.94 (s, 6H); HRMS calcd for C32H25N2O14 (M + H)
+
 683.1125, found 683.1119. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(4-
cyanobenzoate) (92). Yield 38%; colorless amorphous; 
1
H NMR (CDCl3)  8.02–7.99 (m, 4H), 
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7.69–7.66 (m, 4H), 6.73 (s, 2H), 5.91 (s, 2H), 5.81 (s, 2H), 5.16 (d, J = 12.4 Hz, 2H), 5.08 (d, J = 12.4 
Hz, 2H), 3.94 (s, 6H);  HRMS calcd for C34H24N2NaO10 (M + Na)
+
 643.1329, found 643.1314. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) 
bis(benzo[d][1,3]dioxole-5-carboxylate) (93). Yield 85%; colorless amorphous; 
1
H NMR (CDCl3)  
7.53 (m, 2H), 7.34 (s, 2H), 6.77 (s, 2H), 6.75 (s, 2H), 5.99 (s, 4H), 5.93 (s,2H), 5.88 (s, 2H), 5.10 (d, J 
= 12.4 Hz, 2H), 5.02 (d, J = 12.4 Hz, 2H), 3.93 (s, 6H); HRMS calcd for C34H26NaO14 (M + Na)
+
 
681.1220, found 681.1188. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis[6-
(trifluoromethyl)nicotinate] (94). Yield 61%; colorless oil; 
1
H NMR (CDCl3)  9.15 (m, 2H), 8.38 
(m, 2H), 7.71 (m, 2H), 6.74 (s, 2H), 5.93 (dd, J= 1.6, 8.8 Hz, 4H), 5.21 (d, J= 7.6 Hz, 4H), 3.93 (s, 
3H); HRMS calcd for C32H22F6N2NaO10 (M + Na)
+
 731.1076, found 731.1076. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) bis(quinoline-2-
carboxylate) (95). Yield 97%; orange needles; mp: 129–130 C; 1H NMR (CDCl3)  8.25 (m, 2H), 
8.16 (m, 2H), 7.98 (m, 2H), 7.77–7.70 (m, 4H), 7.59–7.55 (m, 2H), 6.86 (s, 2H), 5.88 (dd, J= 1.6, 
19.6 Hz, 4H), 5.32 (d, J= 2.4 Hz, 4H), 3.93 (s, 6H); HRMS calcd for C38H29N2O10 (M + H)
+
 673.1822, 
found 673.1798. 
4,4’-[(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene)]bis(oxy)bis(4-
oxobutanoic acid) (85). To a solution of 69 (26 mg, 0.072 mmol) in anhydrous THF (2.0 mL), 
succinic anhydride (9 mg, 0.090 mmol) and DMAP (5 mg, 0.040 mmol) was added. The mixture was 
refluxed overnight. After cooling to rt, the solution was acidified with 1N HCl aq. and partitioned 
with EtOAc. The organic phase was concentrated. The residue was purified by preparative TLC 
(CH2Cl2:MeOH:TFA =95:5:0.25).  Yield 99%; colorless oil; 
1
H NMR (CDCl3)  6.67 (s, 2H), 5.96 (d, 
J = 16.8 Hz, 4H), 4.94 (d, J = 12.6 Hz, 2H), 4.89 (d, J = 12.6 Hz, 2H), 3.93 (s, 6H), 2.59–2.54 (m, 
8H); HRMS calcd for C26H26NaO14 (M + Na)
+
 585.1220, found 585.1228. 
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Dimethyl 3,3’-diiodo-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate (97). 
Silver trifluoroactate (89 mg, 0.4 mmol) was added to a solution containing 1 (42.1 mg, 0.1 mmol) 
and CHCl3 (1 mL). Then iodine (102.2 mg, 0.4 mmol) was poured into the solution, and the reaction 
mixture was stirred overnight at room temperature. Further isolation was done by preparative TLC 
(hexane-EtOAc: 7:3). Mono- and di-iodo products were found under these conditions. Yield 7%; 
colorless amorphous solid; 
1
HNMR (CDCl3)  6.01 (d, J = 1.6 Hz, 2H), 5.99 (d, J = 1.2 Hz, 2H), 4.05 
(s, 6H), 3.68 (s, 6H); HRMS calcd for C20H16I2NaO10 (M + Na)
+
 692.8731, found 692.8704. 
3,3′-Dibromo-4,4′-dimethoxy-5,6,5′,6′-bis(methylenedioxy)biphenyl-2,2′-dimethanol (98). To a 
stirred solution containing 1 (95.2 mg, 0.165 mmol) and 1 mL anhydrous CH2Cl2 under nitrogen at 
around -20 C (ice with brine), Diisobutylaluminum hydride (DIBAL) (0.83 mL, 0.83 mmol) was 
added dropwise. After one h, another portion of DIBAL (0.4 mL, 0.4 mmol was added and stirring 
continued until starting material disappeared. The reaction was quenched with MeOH (3 mL), 10% 
Rochelle salt solution (3 mL) was added, and the mixture stirred for 30 min. Water was added to the 
mixture, which was then extracted with EtOAc three times, dried over sodium sulfate, and 
concentrated. The compound has low solubility in various solvents (EtOAc, CH2Cl2, MeOH, acetone). 
A small portion was taken for further purification for bioassay. The remaining portion was used in the 
next reaction without further purification. Colorless amorphous solid; 
1
H NMR (CDCl3)  5.96 (s, 
4H), 4.67 (d, J = 12.4 Hz, 2H), 4.26 (d, J = 12 Hz, 2H), 4.09 (s, 6H), 3.19 (bs, 2H); HRMS calcd for 
C18H16Br2NaO8 (M + Na)
+
 542.9089, found 542.9091. 
(3,3′-Dibromo-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) 
dibutyrate (99). Compound 98 (16.8 mg, 0.033 mmol), butyric acid (0.02 mL, 0.21 mmol), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (31.5 mg, 0.16 mmol), 4-
(dimethylamino)pyridine (4.1 mg, 0.033 mmol) were mixed together in CH2Cl2 overnight. The 
reaction mixture was subjected to preparative TLC to give the desired compound, which was 
recrystallized from CH2Cl2 -hexane. Yield 86%; colorless prisms; mp: 109–110 C; 
1
H NMR (CDCl3) 
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 5.94 (d, J = 1.2 Hz, 2H), 5.92 (d, J = 1.6 Hz, 2H), 4.97 (d, J = 1.2 Hz, 2H), 4.89 (d, J = 1.2 Hz, 2H), 
4.06 (s, 6H), 2.18 (t, J = 7.6 Hz, 6H), 1.57 (sex, J = 7.6 Hz, 4H), 0.88 (t, J = 7.2 Hz, 6H); HRMS 
calcd for C28H32Br2NaO10 (M + Na)
+
 682.9926, found 682.9916. 
(4,4′-Dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-diyl)bis(methylene) dibenzoate (100). 
The same procedure as for compound 99, but benzoic acid was used instead of butyric acid. Yield 
74%; colorless prisms; mp: 127–128 C; 1H NMR (CDCl3)  7.92 (d, J = 7.6 Hz, 4H), 7.46–7.52 (m, 
2H), 7.36 (t, J = 7.6 Hz, 4H), 5.88 (s, 2H), 5.70 (s, 2H), 5.31 (d, J = 11.6 Hz, 2H), 5.12 (d, J = 11.6 
Hz, 2H), 4.07 (s, 3H); HRMS calcd for C32H24Br2NaO10 (M + Na)
+
 750.9613, found 750.9614. 
3,3′-Dibromo-4,4′-dimethoxy-5,6,5′,6′-bis(methylenedioxy)biphenyl-2-hydroxymethyl-2′-
carboxylic acid (103). To a stirred solution containing anhydrous THF (5 mL) and 102 (69.4 mg, 
0.13 mmol) under nitrogen, sodium borohydride (15 mg, 0.39 mmol), followed by MeOH (0.1 mL), 
was added at room temperature. After the reaction was completed, 2 N HCl solution was added to 
acidify the solution to pH= 2. The solution was extracted with CH2Cl2 (with less than 10% MeOH), 
and the organic layer was dried over sodium sulfate. Flash chromatography (CH2Cl2—MeOH) was 
used to purify the desired compound. Yield 88%; amorphous solid; 
1
H NMR (DMSO, 400 MHz)  
13.2 (bs), 6.04 (d, J = 34 Hz, 2H), 5.97 (d, J = 40 Hz, 2H), 4.55 (bs), 4.28 (dd, J = 11.2, 25.8 Hz, 4H), 
3.99 (s, 6H), 3.95 (s, 6H); HRMS calcd for C18H14Br2NaO9 (M + Na)
+
 582.9029, found 582.9038. 
Cell Culture 
A549 (lung carcinoma), DU-145 (prostate cancer), K562 (chronic myelogenous leukemia) and KB 
(epidermoid carcinoma) cell lines (ATCC) were obtained from Lineberger Cancer Center (UNC-CH). 
KBvin (vincristine-resistant KB subline) was generously provided by Professor Y.-C. Cheng, Yale 
University, CT. Cells were cultured in RPMI 1640 medium with 25 mM HEPES and 2 mM L-
glutamine (Mediatech), supplemented with 10% heat inactivated fetal bovine serum (Hyclone), 100 
IU penicillin, 100 µg streptomycin, and 0.25 µg/mL amphotericin B (Mediatech). KBvin cells were 
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maintained in media containing 100 nM vincristine and were cultured for 7–10 days without 
vincristine before experiments were performed. Cells were maintained at 37 C in a humidied 5% 
CO2 atmosphere. The cells were sub-cultured every 3–4 days. 
Cytotoxicity Analysis (SRB assay) 
Cytotoxicity was determined by the sulforhodamine B (SRB) colorimetric assay. Cells (3-5 × 10
3
 
cells/well) were seeded in 96-well plates filled with culture medium containing various 
concentrations of samples for 3 days. At the end of the exposure period, the supernatant was removed 
and fresh culture medium (100 µL) was added to each well. The cells were fixed with 50% 
trichloroacetic acid solution for 30 min, and 0.04% SRB (Sigma Chemical Co.) was added to each 
well. After 30 min incubation, the plates were washed, and dye was dissolved in 10 mM unbuffered 
Tris base and read at 515 nm on Microplate Reader ELx800 (Bio-Tek instruments, Winooski, VT) 
with a Gen5 software. 
MDR Reversal Activity 
For screening of chemosensitizing ability of test compounds, MDR and parental sensitive cells were 
incubated with test compound in the presence and absence of paclitaxel at a fixed concentration that 
did not affect the cell growth. Vincristine-resistant KB (KBvin) and parental KB cells were seeded at 
5–7 × 103 cells/well into 96-well plates and incubated with 10 µM test compound with and without 
paclitaxel at 100 nM or 1 nM, respectively. After 3 days incubation, cell density was determined with 
a SRB assay. To assess the reversal activity of MDR by candidate compounds, a comparison was 
made of the IC50 values of anticancer drug (vincristine, paclitaxel, and doxorubicin) in the presence 
and absence of 10 µM of each test compound. IC50 values were calculated by log–linear interpolation 
of data points. Verapamil, a known P-gp inhibitor/modulator, was used as the positive control in all of 
the experiments. The reversal fold values, as potency parameter of test compounds, were calculated 
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as: Reversal fold = IC50 (anticancer drug alone) / IC50 (anticancer drug + test compound). All 
experiments were performed at least three times. 
Measurement of the Intracellular Accumulation of calcein-AM and Doxorubicin (Dox)  
KBvin cells (5 × 10
3
 cell/well) were seeded in 96-well plates and pre-incubated for 72 h in a 5% CO2 
incubator at 37 °C. Then, the cells were washed with the culture medium and pretreated with samples 
or vehicle 1 h before calcein or doxorubicin was added at a final concentration of 10 µM. After 3 h 
incubation, the medium was removed by aspiration and the cells were washed with ice-cold PBS, and 
lysed with 1% sodium dodecyl sulfate (SDS) in PBS. Calcein or doxorubicin-associated mean 
fluorescence intensity were measured at Ex: 494 nm/Em: 517 nm or Ex: 488 nm/Em: 580 nm 
respectively with a fluorescence microplate reader (Plate Chameleon Multilabel Detection Platform, 
Hidex Oy, Turku, Finland) with MikroWin software. Verapamil was used as the positive control. All 
data were calculated as the ratio of doxorubicin fluorescence with test compound divided by 
doxorubicin fluorescence without test compound after subtraction of the fluorescence of the control. 
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Chapter 4 
Novel Analogs of Dimethyl Dicarboxylate Biphenyl as Potent Cancer 
Chemopreventive Agents 
 
4.1 Introduction 
Carcinogenesis is a complex process involving initiation, promotion, and progression steps. The 
promotion step is a long and reversible process and has been widely studied.
1
  Inhibition of this step, 
which is known as cancer prevention, should be an effective approach to control cancer, and various 
phytochemicals, such as carotenoids, green tea polyphenols, curcumin, glycyrrhizin and its related 
compounds, from herbs and medicinal plants have been reported to exhibit cancer preventive ability.
2
  
However, despite its recognized effectiveness at blocking the long process of cancer development, 
relatively limited numbers of studies have been reported on cancer prevention. Therefore, more 
efforts aimed at the discovery and development of cancer preventive agents are needed.  To evaluate 
cancer preventive ability, a short term in vitro assay can be applied for determining cancer preventive 
agents. Epstein-Barr virus (EBV) is known to be activated by tumor promoters to produce early 
antigens. Inhibition of Epstein Barr virus early antigen (EBV-EA) is used to evaluate antitumor 
promoting ability.
3
  
Dimethyl dicarboxylate biphenyl (DDB, 1), a synthetic analog of schisandrin C (Figure 4.1) 
isolated from Schizandrae chinensis, is a hepatoprotective agent used to treat hepatitis B in China and 
to treat HBV and HCV in many Asian countries.
4, 5
 In addition, DDB was shown to reverse multidrug 
resistant cancer cells, breast carcinoma MCF-7/Adr, KBv200, and Bel7402 in vitro and increase 
antitumor activity of vincristine to KBv200 xenografts in vivo.
5
 Moreover, DDB also 
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prevented the oncogenic transformation of WB-F344 rat liver epithelial cells induced by 3-
methylcholanthrene and 12-O-tetradecanoyl phorbal 13-acetate (TPA) at the doses of 1, 2, and 4 
µmol/L. In a soft-agar colony formation assay, colony numbers were reduced in transformed cells 
treated with DDB. Furthermore, DDB could inhibit TPA-induced down-regulation of the gap 
junctional intercellular communication (GJIC).
4
 These findings suggest that DDB has 
chemopreventive potential.  
Figure 4.1. Structures of DDB and Schisandrin C 
 
In our design of new DDB analogs, we found that known DDB analogs with different 
functional groups were previously synthesized and tested for cancer preventive ability.
6
 In addition, 
while many 2,2′-carboxylate ester derivatives have been covered in various patents and papers, the 
modification of a 2,2′-bismethylene alcohol DDB intermediate (69) appears to be a new avenue of 
exploration. A prenylated side chain, which has been found to be effective in cancer chemoprevention 
studies of other compound classes, was a logical first choice.
7
 In addition, short unsaturated fatty acid 
chains, which have resulted in good chemopreventive activity in betulinic acid derivatives, were 
included in our modification scheme.
8
 Water-solubility is an important factor for drug discovery, 
because it is always associated with important pharmaceutical drug indices. Thus, a hydrophilic 
carboxylic acid moiety was incorporated into new DDB analogs by coupling the 2,2′-bismethylene 
alcohol DDB intermediate with succinic and glutaric anhydrides. Accordingly, in this study, we will 
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discuss the synthesis of new DDB analogs (Figure 4.2), structure-activity relationship findings, and 
EBV-EA inhibition ability. In vivo data of the most potent compounds are also described.  
 
4.2 Results and Discussion 
Chemistry.  
Compounds 101 were synthesized following literature methods.
6
 Reduction of 1 and 3,3′-
dibromo-DDB (96) with diisobutylaluminum hydride (DIBAL) resulted in the related 2,2′-methylene 
alcohols 69 and 98, respectively.  Diols 69 and 98 were then converted to various ester and ether 
analogs as shown in Figure 2. Esterifications of 69 and 98 were carried out in the presence of either 
excess carboxylic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), and 4-
dimethylaminopyridine (DMAP) or acyl chloride and triethylamine at 0C. A hydrophilic group was 
introduced by coupling with succinic anhydride or glutaric anhydride. Bisprenyl ether 106 and mono-
geranyl ether 107 were obtained by Williamson ether synthesis of 69 with prenylbromide and 
geranylbromide, respectively, in the presence of sodium hydride. It should be noted that the 
bisgeranyl ether was not stable and decomposed easily after purification. Therefore, only the mono-
geranyl ether 107 was obtained.  
In vitro EBV-EA inhibition of DDB analogs.  
All analogs were evaluated in a short-term in vitro EBV-EA inhibition assay to determine their 
cancer prevention potential, and the results are shown in Table 1. All tested compounds showed 
relatively potent inhibition of EBV activation. The analogs with unsaturated alkyl side chains and 
terminal carboxylic acids, such as 82-85, 93, 104-107, significantly inhibited EBV-EA activation, 
showing 95.9–100.0% inhibition at the highest tested concentration, and showed greater inhibitory 
effects than the parent compound 1. In particular, the most potent compound 106 displayed 100% 
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inhibition at 1 × 10
3
 mol ratio/TPA, and 78.4%, 49.7% and 10.9% inhibition at 5 × 10
2
, 1 × 10
2
, 1 × 
10 mol ratio/TPA, respectively, with an IC50 value of 252 mol ratio/TPA. At the higher concentrations 
of 1 × 10
3
 and 5 × 10
2
 mol ratio/TPA, the inhibition values with 106 were comparable to those of 
curcumin, which is a known potent cancer preventive agent. Moreover, even at low concentrations, 
106 inhibited EBV-EA activation and the inhibitory effects of 106 were notably greater than those of 
curcumin at 1 × 10
2
 and 1 × 10 mol ratio/TPA. The analogs with prenyl-like unsaturated alkyl groups, 
such as 82-84, 106, and 107 exhibited relatively high activity. This finding is consistent with other 
reports that a prenyl-like group tends to enhance the inhibitory effect on EBA activation.
7
 The 
presence of an aromatic ring on the C-2,2′ side chain, as found in 100, 105, and 93, reduced the 
inhibitory effect on EBV-EA activation. The effect of bromide depended on the functional group at 
C-2 and -2′. With 2,2′-biscarbomethoxy substitution, the 3,3′-dibromo analog 96 showed lower 
potency than the parent compound 1, while with 2,2′-bisbutyryloxymethyl substitution, the 3,3′-
dibromo analog 99 showed higher potency than the related non-brominated compound 72. The esters 
70–72 and 77 with linear saturated fatty acids of varying lengths demonstrated almost equal potency, 
indicating that the length of the alkyl chain is not crucial for the activity; however, the activity 
decreased with a chain length of 12 carbons (analog 79).  Compounds 85 and 104 with terminal 
carboxylic acids on the 2,2′-ester groups exhibited better activity than the parent compound 1. In a 
direct comparison, the succinate side chain (85) was better than glutarate side chain (104) in terms of 
potency.  
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Table 4.1. DDB Analogs and Their EBV-EA Inhibition Ability.    
No.  R
1
 R
2
 
Percentage of EBV-EA positive cells 
Concentration (mol ratio/TPA
b
) IC50
d
 
1000 500 100 10 
1 
 
H 
 
6.3 (70)
c
 32.8 67.8 97.3 341 
96 
Br 
 
14.6 (60) 40.2 76.0 100 403 
98  8.4 (60) 36.0 71.2 100 358 
101 
 
7.9 (60) 35.8 68.2 98.6 349 
99 
 
7.9 (60) 35.8 68.2 98.6 349 
100 
 
11.5 (60) 38.6 75.5 100 389 
70 
 
 
 
13.1 (60) 37.0 71.3 100 390 
71 
 
12.0 (60) 35.9 70.0 100 381 
72 
 
11.2 (60) 37.0 72.0 100 380 
77 
 
10.3 (60) 37.4 71.7 100 379 
79 
 
15.6 (60) 41.0 76.9 100 426 
82 
 
3.1 (70) 27.0 54.9 93.4 278 
83 
 
1.7 (70) 23.5 51.6 90.3 260 
84 
 
2.9 (70) 25.1 53.7 91.7 269 
85 
 
2.1 (60) 24.8 52.6 91.5 265 
104 
 
4.1 (60) 28.6 57.4 96.6 287 
105 
 
9.5 (60) 36.0 71.0 100 372 
93 
 
8.9 (60) 35.7 71.5 100 369 
106 
 
0 (70) 21.6 50.3 89.1 252 
107
a
 
 
1.9 (70) 24.6 52.9 91.6 263 
curcumin   0 (60) 21.1 80.1 100 379 
     Notes: 
a
 In this structure, only one R
2
 is the moiety shown above; the other R
2
 is a hydrogen group. 
b 
TPA concentration is 32 pmol/mL. 
c 
Values in parentheses are viability percentages of Raji cells. 
d 
IC50 in mol/ratio TPA. 
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Figure 4.2. Syntheses of DDB analogs 
 
In vivo mouse skin carcinogenesis inhibition.  
The in vitro inhibitory effects determined in the EBV-EA assay generally have been found to 
correlate well with in vivo inhibitory effects on tumor promotion as reported in many studies.
9-13
 
Therefore, based on the in vitro data, only three of the most potent compounds (83, 85, and 106) were 
examined in a two-stage in vivo skin carcinogenesis test evaluating mouse skin papilloma induced by 
DMBA as an initiator and TPA as a promoter (Table 4.2). The compounds’ activities were 
determined by both the percentage of papilloma-bearing mice (Figure 4.3A) and the average number 
of papillomas/mouse (Figure 4.3B), compared with the positive control. All three compounds delayed 
the appearance of the first tumor for two weeks compared with the positive control.  In the positive 
control group, 6.6, 40, and 100% of the mice bore papillomas after 6, 8, and 11 weeks of promotion, 
respectively, and 6.3 papillomas were formed/mouse after 15 weeks. However, in the groups treated 
with compounds 83 and 106, 0, 7, and 33% of the mice bore papillomas at weeks 6, 8, and 11, 
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respectively, and 4.4–5.1 papillomas/mouse were found with all three tested compounds, even after 
15 weeks of promotion.  
Table 4.2.  In vivo inhibitory effects of 83, 85, and 106 on two-stage mouse carcinogenesis 
Week Papilloma (%) Papillomas/Mouse 
 Positive 
controla 
83
b
 85
b
 106
b
 Positive 
controla 
83
b
 85
b
 106
b
 
1 0 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 
6 6.6 0 0 0 0.4 0 0 0 
7 20.0 0 0 0 0.9 0 0 0 
8 40.0 6.6 13.3 6.6 1.8 0.7 0.9 0.6 
9 73.3 13.3 26.6 13.3 2.4 1.6 2.0 1.4 
10 86.6 26.6 33.3 26.6 3.5 2.0 2.2 1.8 
11 100 33.3 40.0 33.3 3.9 2.4 2.6 2.0 
12 100 40.0 53.3 40.0 4.3 2.6 2.9 2.4 
13 100 53.3 66.6 53.3 5.2 3.3 3.6 3.1 
14 100 66.6 73.3 66.6 5.9 4.3 4.5 4.0 
15 100 73.3 73.3 66.6 6.3 4.6 5.1 4.4 
Note: 
a
 The positive control is DMBA (390 nmol) plus TPA (1.7 nmol) b The concentration of compound is 85 nmol. 
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Figure 4.3. Inhibitory effects of compounds 83, 85, and 106 on DMBA-TPA mouse skin 
carcinogenesis. Tumor formation in all mice was initiated with DMBA (390 nmol) and promoted 
with TPA (1.7 nmol) twice weekly beginning 1 week after initiation. (A) Papilloma percentage in 
mice. (B) Average number of papillomas/mouse. (◆) Control TPA alone; (■) TPA + compound 83 
(85 nmol); (×) TPA+ compound 85 (85 nmol); (▲) TPA + compound 106 (85 nmol). After 15 weeks 
of promotion, a significant difference in the number of papillomas/mouse between the treated groups 
and the control group was evident (p ＜0.05). In Fig. 4.3A, the trace for compound 106 is 
superimposed with that for compound 83. 
  
Figure 4.4. Pictures of Tested Rat of In Vivo Two Stage Mouse Skin Carcinogenesis Assay. 
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4.3 Conclusions 
Several 2,2′-bismethyl ester and ether DDB analogs were designed and synthesized. All analogs 
showed potent EBV-EA inhibition in vitro. Among them, analogs 82–85, 104, 106, and 107 with 
unsaturated side chains or terminal carboxylic acids significantly inhibited the EBV-EA activation. In 
particular, prenyl derivative 106 showed the highest inhibitory effects (100% , 78.4%, 49.7% and 
10.9% inhibition at 1 × 10
3
, 5 × 10
2
, 1 × 10
2
, 1 × 10 mol ratio/TPA, respectively), which were greater 
than those of curcumin at the low concentrations. In an in vivo assay, DDB analogs 83, 85, and 106 
also delayed the formation of mouse skin papillomas after initiation and promotion by a cancer 
promoting substance. DDB has been used clinically, which implies that DDB analogs have good 
probability to be further developed as potent cancer preventive agents for clinical use. Thus, DDB 
analog 106 could be a valuable candidate as a cancer preventive agent or as a lead for the 
development of new antitumor promoter drugs. 
 
4.4 Material and Methods 
Chemistry 
1
H NMR (400 MHz) spectra were measured on a Varian Inova spectrometer with TMS as the internal 
standard. All chemical shifts are reported in ppm. Mass spectra were measured on a Shimazu LCMS-
2010 (ESI-MS). All reactions were monitored by thin-layer chromatography (TLC) on aluminum 
sheets (silica gel 60 F254 plate, 20 × 20, Merk). Melting points were recorded on a Fisher Johns 
melting apparatus without correction. Medium-pressure column chromatography was used in Biotage 
Flash and Isco companion systems with silica 40 µM columns from Grace Inc. All final compounds 
were > 95% purity based on HPLC. Anhydrous solvents were purchased from commercial suppliers. 
General procedure for compounds 70, 72, 77, 82-84, and 99-100 
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To a solution of 69 in dichloromethane, the appropriate carboxylic acid (5 eq. mole), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (5 eq. mole) and 4-
(dimethylamino)pyridine (1 eq. mole) were added and stirred overnight. The reaction mixture was 
subjected to preparative TLC (hexane- ethyl acetate) without work-up. 
Compound 99: Yield, 86%; Colorless prisms; mp: 109-110C; 1H NMR (CDCl3)  5.94 (d, J = 1.2 Hz, 
2H), 5.92 (d, J = 1.6 Hz, 2H), 4.97 (d, J = 1.2 Hz, 2H), 4.89 (d, J = 1.2 Hz, 2H), 4.06 (s, 6H), 2.18 (t, 
J = 7.6 Hz, 6H), 1.57 (sext, J = 7.6 Hz, 4H), 0.88 (t, J = 7.2 Hz, 6H); ESI-MS m/z: 678 [M+18(H2O)]
+
. 
Compound 100: Yield, 75%; Colorless prisms; mp: 127-128C; 1H NMR (CDCl3)  7.92 (d, J = 7.6 
Hz, 4H), 7.46–7.52 (m, 2H), 7.36 (t, J = 7.6 Hz, 4H), 5.88 (s, 2H), 5.70 (s, 2H), 5.31 (d, J = 11.6 Hz, 
2H), 5.12 (d, J = 11.6 Hz, 2H), 4.07 (s, 3H); ESI-MS m/z: 746 [M+18(H2O)]
+
.  
Compound 70: Yield, 85%; Colorless oil; 
1
H NMR (CDCl3)  6.69 (s, 2H), 5.97 (s, 2H), 5.95 (s, 2H), 
4.85 (s, 4H), 3.95 (s, 6H), 1.99 (s, 6H); ESI-MS m/z: 464 [M+18(H2O)]
+
.  
Compound 72: Yield, 97%; Colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 1H), 5.96 (d, J = 1.4 Hz, 2H), 
5.95 (d, J = 1.4 Hz, 2H) 4.86 (s, 4H), 3.93 (s, 6H), 2.22 (t, J = 7.2 Hz, 4H), 1.59 (m, 4H), 0.90 (t, J = 
7.2 Hz, 6H); ESI-MS m/z: 520 [M+18(H2O)]
+
.  
Compound 77: Yield, 99%; Colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.96 (d, J = 1.5 Hz, 2H), 
5.94 (d, J = 1.5 Hz, 2H), 4.85 (s, 4H), 3.93 (s, 6H), 2.23 (t, J = 7.6 Hz, 4H), 1.54 (pent, J = 7.6 Hz, 
4H), 1.34–1.25 (m, 4H), 0.88 (t, J = 7.6 Hz, 6H); ESI-MS m/z: 548 [M+18(H2O)]
+
.  
Compound 79: Yield, 88%; Colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.96 (d, J = 1.5 Hz, 2H), 
5.94 (d, J = 1.5 Hz, 2H), 4.85 (s, 4H), 3.93 (s, 6H), 2.24–2.20 (m, 4H), 1.57–1.19 (m), 0.87 (t, J = 6.8 
Hz, 6H); ESI-MS m/z: 744 [M+18(H2O)]
+
. 
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Compound 82: Yield, 8%; Colorless oil; 
1
H NMR (CDCl3)  6.96–6.87 (m), 6.7 (s, 2H), 5.94 (s, 4H), 
5.78 (d, J= 15.6 Hz, 2H), 4.94 (d, J = 12.4 Hz, 2H), 4.85 (d, J = 12.4 Hz, 2H), 3.93 (s, 6H), 1.85 (d, J 
= 6.8 Hz, 6H); ESI-MS m/z: 544 [M+46(HCOOH)]
+
.  
Compound 83: Yield, 51%; Colorless oil; 
1
H NMR (CDCl3)  6.70 (s, 2H), 5.94 (d, J = 1.5 Hz, 2H), 
5.93 (d, J = 1.5 Hz, 2H), 5.62 (s, 2H), 4.95 (d, J = 12.5 Hz, 2H), 4.82 (d, J = 12.5 Hz, 2H), 3.93 (s, 
6H), 2.12 (s, 6H), 1.86 (s, 6H); ESI-MS m/z: 568 [M+42(CH3CN+H)]
+
.  
Compound 84: Yield, 55%; Colorless oil; 
1
H NMR (CDCl3)  7.19 (d, J = 9.8 Hz, 1H), 7.15 (d, J = 
9.8 Hz, 1H), 6.70 (s, 2H), 6.18–6.08 (m, 4H), 5.93 (d, J = 1.5 Hz, 4H), 5.71 (s, 1H), 5.68 (s, 1H), 4.96 
(d, J = 12.3 Hz, 4H), 4.87 (d, J = 12.3 Hz, 4H), 3.93 (s, 6H), 1.83 (d, J= 5.2 Hz, 6H); ESI-MS m/z: 
516 [M-34]
+
. 
General procedure for compounds 71, 105, and 93 
Compound 69 and triethylamine (5–10 eq. mole) were first added to anhydrous dichloromethane, and 
then the appropriate acyl chloride (2.2 eq. mole) was added at 0C under nitrogen. The reaction was 
warmed gradually to room temperature and stirred for 1–3 h. After the reaction was completed, water 
and saturated sodium carbonate solution were added and the reaction mixture was extracted with 
dichloromethane, dried over sodium sulfate, and concentrated. Further purification was done by 
combiflash (hexane-ethyl acetate gradient). 
Compound 71: Yield, 99%; Colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.95 (d, J = 6.5 Hz, 4H), 
4.85 (s, 4H), 3.93 (s, 6H), 2.26 (q, J = 7.2 Hz, 4H), 1.08 (t, J = 7.6 Hz, 6H); ESI-MS m/z: 492 
[M+18(H2O)]
+
.
 
Compound 17: Yield, 85%; Orange amorphous solid; 
1
H NMR (CDCl3)  7.43 (s, 2H), 
7.34 (d, J = 15.6Hz, 2H), 6.73 (s, 2H), 6.58 (d, J = 1.2 Hz, 2H), 6.44 (m, 2H), 6.22 (d, J = 16 Hz, 2H), 
5.95 (d, J = 2.4 Hz, 4H), 5.01 (d, J = 12.4 Hz, 2H), 4.95 (d, J = 12.4 Hz, 2H), 3.93 (s, 6H); ESI-MS 
m/z: 620 [M+18(H2O)]
+
.  
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Compound 93: Yield, 85%; Colorless amorphous solid; 
1
H NMR (CDCl3)  7.53 (m, 2H), 7.34 (s, 
2H), 6.77 (s, 2H), 6.75 (s, 2H), 5.99 (s, 4H), 5.93 (s, 2H), 5.88 (s, 2H), 5.10 (d, J = 12.4 Hz, 2H), 5.02 
(d, J = 12.4 Hz, 2H), 3.93 (s, 6H); ESI-MS m/z: 676 [M+18(H2O)]
+
. 
General procedure for compounds 85 and 104 
Succinic anhydride (for 85) or glutaric anhydride (for 104) (1.2 eq. mole) and DMAP (5% w/w) was 
added to a flask containing 69 in anhydrous tetrahydrofuran. The solution was refluxed under 
nitrogen overnight. A solution of 1N hydrochloric acid was added to acidify the reaction mixture and 
ethyl acetate was used three times successively for extraction of the aqueous layer. Preparative TLC 
(dichloromethane–methanol) was applied to purify the desired compound from the combined aqueous 
extracts.  
Compound 85: Yield, 28%; Colorless oil; 
1
H NMR (CDCl3)  6.67 (s, 2H), 5.96 (d, J = 16.8 Hz, 4H), 
4.94 (d, J = 12.6 Hz, 2H), 4.89 (d, J = 12.6 Hz, 2H), 3.93 (s, 6H), 2.59–2.54 (m, 8H); ESI-MS m/z: 
580 [M+18(H2O)]
+
. 
  
Compound 104: Yield, 7%; Colorless oil; 
1
H NMR (CDCl3)  6.68 (s, 2H), 5.96 (d, J = 13.6 Hz, 4H), 
4.90 (d, J = 12.5 Hz, 2H), 4.84 (d, J = 12.5 Hz, 2H), 2.38–2.31 (m, 8H), 1.93–1.84 (m, 4H); ESI-MS 
m/z: 608 [M+18(H2O)]
+
. 
General procedure for compounds 106 and 107 
Compound 69 in anhydrous tetrahydrofuran was added slowly to a flask with sodium hydride (5 eq. 
mole) in anhydrous tetrahydrofuran under nitrogen at 0C. After 10 min, 3,3-dimethylallyl bromide (3 
eq. mole for 106) or geranyl bromide (3 eq. mole for 107) was added. When the starting material 
disappeared, water was added to quench the reaction. The aqueous solution was partitioned with ethyl 
acetate. The organic layer was washed with sodium bicarbonate solution and then dried over sodium 
sulfate. Desired compounds were purified by preparative TLC with a hexane-ethyl acetate system. 
77 
 
Compound 106: Yield, 43%; Colorless oil; 
1
H NMR (CDCl3)  6.78 (s, 2H), 5.92 (s, 4H), 5.23 (m, 
2H), 4.23 (d, J = 12.1 Hz, 2H), 4.16 (d, J = 12.1 Hz, 2H), 3.94 (s, 6H), 3.82 (d, J = 6.9 Hz, 4H), 1.70 
(s, 6H), 1.59 (s, 6H); ESI-MS m/z: 521 [M+23(Na)]
+
.  
Compound 107: Yield, 47%; Colorless oil; 
1
H NMR (CDCl3)  6.76 (s, 1H), 6.69 (s, 1H), 5.69–
5.93(m, 4H), 5.11–5.05 (m, 2H), 4.39–4.11 (m, 4H), 3.94 (s, 6H), 3.84 (m, 2H), 2.10–1.95 (m, 4H), 
1.67 (s, 3H), 1.58 (s, 3H), 1.57 (s, 3H); ESI-MS m/z: 481 [M-17(OH)]
+
. 
In vitro EBV-EA activation experiment 
Raji cells (10
6
 cells/mL) (with EBV latent, non-producing cells) were incubated at 37C for 48 h in 
RPMI 1640 medium with 10% fetal calf serum (FCS) with n-butyric acid (4 mmol), TPA (32 pmol), 
and test compounds at various concentrations (10, 100, 500, 1000 mol ratio/TPA). Smears were made 
from the cell suspension, and the EBV-EA inducing cells were stained by an indirect 
immunofluorescence technique (anti-human EBV-EA antibody followed by IgG-FITC tag). In each 
assay, at least 500 cells were counted and the number of stained cells (positive cells) was recorded. 
Each assay was repeated three times for one test compound. The EBV-EA-inhibiting activity of the 
test compound was estimated on the basis of the percentage of the number of positive cells compared 
with that of the control without the test compound. The viability of the cells was assayed by the 
TrypanBlue staining method. For the determination of cytotoxicity, the cell viability was required to 
be more than 60%.
14
 
In vivo two-stage mouse skin carcinogenesis test 
A total of 30 female ICR mice (6 weeks old, purchased from SLC Co. Ltd., Shizouka, Japan) were 
used. Two groups, with each group consisting of 15 animals, housed at five/cage, were painted with 
390 nmol of 7,12-dimethylbenz[a]anthracene (DMBA) in acetone, 0.1 mL/mouse, on a shaved region 
of skin on the back. After 1 week, the mice were treated topically with 1.7 nmol of TPA in acetone 
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(0.1 mol) twice a week for 20 weeks. One hour prior to TPA treatment, the animals in group I were 
treated with acetone (0.1 mL) alone, serving as a promotion-positive control. The animals in group II 
were treated with the test compound (85 nmol) in acetone (0.1 mL). The incidence of papilloma was 
observed weekly for 15 weeks. The differences in the occurrence of mouse skin papillomas between 
the control and treatment groups were analyzed by means of the Student’s t-test after 15 weeks of 
promotion. 
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Chapter 5 
 A-ring Modified Betulinic Acid Analogs as Novel Cancer Preventive, 
Anticancer and Anti-HIV Agents 
 
5.1 Introduction 
Triterpenoids are abundant in the plant kingdom, and many of them exhibit anti-HIV activity.
1, 2
 
A huge break-through occurred in this research field when studies showed that betulinic acid (BA) 
was potent against HIV in 1994, which led to the discovery and development of a new class of anti-
HIV agents, maturation inhibitors (MI). Bevirimat, 3-O-(3′,3′-dimethylsuccinyl)betulinic acid with 
EC50 < 0.35 nM and a selective index of 20,000, is now in phase II clinical trial as the first drug in the 
class of maturation inhibitors. 
3, 4
 MIs interfere with viral Gag precursor polyprotein and prevent 
conversion of p25 (CA-SP1) to functional p24 (CA), which leads to production of noninfectious 
immature HIV-1 particles. Importantly, MIs retain their high anti-HIV potency against different viral 
strains that are resistant to current antiviral therapies.
5
 
Extensive studies have been reported on modification of BA, mainly on the C-3 and C-28 
positions, to enhance anti-HIV activity (Figure 5.1). Analogs have included conformationally 
restricted 3-O-acyl BA,
6
 3-O-monosuccinyl BA,
6
 and 3,28-disubstituted 28-piperidine BA 
derivatives.
7
 In addition, a lupane-like triterpene with a five-membered ring A, 2β-carboxy-3β-
hydroxyl-norlupA(1)-20(29)-en-28-oic acid (108), also showed anti-HIV activity with EC50 < 0.13 
μM.8 Moreover, a 2,3-seco-lupane triterpene, 16 β-hydroxy-2,3-seco-lup-20(29)-ene-2,3-dioic acid 
(109), exhibited significant anti-HIV protease activity, which suggested that a seco A-ring with two 
carboxylic acids might increase protease activity.
9
 Meanwhile, lancifoic acid A (110), which 
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exhibited moderate anti-HIV activity (EC50 = 33.2 μM) contained a secocycloartane A ring.
10
 Another 
anti-HIV (EC50 5.1 μM) natural product, 3,4-seco-(24Z)-cycloart-4(28),24-diene-3,26-dioic acid 26-
methyl ester (111), isolated from Illicium verum, also has a secoclycoartane A ring. 
11
 
 
In addition to anti-HIV activity, a 3,4-seco lanostane triterpene (112) exhibited inhibitory effects 
in an EBV-EA activation assay in Raji cells.
12
 Moreover, some limonoids with an A-ring lactone [ex. 
nomilin (113)] have shown various actions against neuroblastoma cancer cells (SH-SY5Y), including 
apoptosis induction, cancer cell cycle arrest, and aneuploidic effect.
13
 3,4-Seco ursolic acid 
derivatives were also obtained by first constructing and then opening a lactone ring. These derivatives 
induced cell cycle arrest and apoptosis in a human bladder cancer cell line (NTUB1).
14
 
 
Based on these findings and studies, novel A-ring modified BA derivatives were designed, 
synthesized, and evaluated for anti-HIV, anticancer, and cancer preventive activities. 
5.2 Design and Synthesis 
3,4-Seco analogs, 120–132, were designed and synthesized through oxepanone ring-A analogs, 
117–119, which could provide information on the effect of an expanded ring-A (Scheme 5.1). Based 
on previous study, an N-heptane acetamide side chain can enhance anti-HIV activity, either anti-
maturation or anti-entry activity.
15
 Therefore, this side chain was included in the analog design as 
shown in 123, 124, and 130–132. A benzylic group was selected to serve as a protective group, as 
well as to assess the biological effect of aromatic substitution. Betulin, a commercial available 
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pentacyclic triterpene, was used as starting material. Jone’s oxidation of betulin easily produced 114, 
with a 3-ketone and 28-carboxylic acid. Compound 114 was converted separately to benzyl ester 115 
and amide 116, which has the same amide side chain found in A43-D, a prototypic HIV entry 
inhibitor. A Baeyer-Villiger reaction using 3-chloroperbenzoic acid (mCPBA) produced oxepanone 
ring A-analogs, 117–119. Acid-catalytic lactone ring opening in methanol led to the related 4-
methylene-3-methyl ester analogs 120, 122, and 123, respectively. The prop-1-en-2-yl group 
generated at C-5 is similar to a prenyl group, which is critical in cancer prevention research.
16
 From 
previous study, compounds 109–112 have an acetic or propanoic acid side chain, and they showed 
good protease inhibition. Therefore, the acids 121 and 124 were prepared by hydrolysis of the methyl 
ester groups in 120 and 123. Hydroboration of the double bond in 122 gave a terminal hydroxy group 
in 125. Esterification of this hydroxy group with 2,2-dimethylsuccinic or glutaric anhydride, followed 
by catalytic debenzylation, gave compounds 127 and 128, respectively. From the studies leading to 
bevirimat, a dimethylsuccinate side chain can effectively increase anti-HIV activity. Glutaric acid was 
selected to compare the effect of chain length. Alternatively, catalytic debenzylation of 125 gave 126, 
which was esterified using acetic anhydride to provide acetate 129. Amidation of the free C-28 
carboxylic acid gave the amide 130. The acetyl group served as a protective group, as well as 
provided a polarity comparison with the corresponding hydroxy group, after the methyl ester and 
acetate on 130 were hydrolyzed to obtain 131. The treatment of 131 with 2,2-dimethylsuccinic 
anhydride produced 132. 
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Scheme 5.1 Synthetic Scheme of Dihydro-BA A-Ring Modified Derivatives. 
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5.3 Results and Discussion 
5.3.1 Results of Cytotoxicity Activity 
Compounds 119–121, 123, 124, 126, 127, and 129–132 were evaluated for cytotoxicity against four 
different human cancer cell lines, A549 (lung carcinoma), DU-145 (prostate cancer), KB 
(nasopharyngeal carcinoma), and KBvin (KB multidrug resistant subline). Compounds 120, 123, 126, 
and 129 exhibited cytotoxicity (IC50< 10 µM) against at least three four cell lines, (Table 5.1). Analog 
120 with a 3-methyl ester, 4,23-vinyl group, and 28-carboxylic acid was the most potent. Compound 
121 with a 3-carboxylic acid group rather than methyl ester was inactive, indicating that a more 
hydrophobic group may be preferred at this position. From the data for 120 and 123, addition of a 28-
N-heptane acetamide group in the latter compound decreased the activity. Comparison of 120, 126, 
and 129 resulted in the general rank order of potency, 120 (C=CH2) > 129 (CH-CH2OAc) > 126 (CH-
CH2OH). Interestingly, especially 126 was more cytotoxic against the multidrug resistant strain, 
KBvin (IC50 = 4.8 µM) than its parent strain KB (IC50 = 8.03 µM), suggesting a potential 
chemosensitizing activity. Further evaluation of this possible effect is ongoing. A brief schematic 
summary of the structure/activity results is shown below. 
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Table 5.1. Cytotoxicity of BA A-ring Opened Derivatives 
 IC50 (µM) 
Compd A549 DU-145 KB KBvin 
119 >10 >10 >10 9.01  0.3 
120 5.59  0.3 4.46  0.3 5.08  0.3 4.55  0.4 
121 >10 >10 >10 >10 
123 >10 6.35  0.2 8.79  0.06 9.48  0.8 
124 >10 >10 >10 >10 
126 6.78  0.5 7.16  0.7 8.03  0.5 4.86  0.4 
127 9.68  0.5 >10 >10 >10 
129 6.18  0.03 5.29  0.5 7.01  0.5 5.02  0.3 
130 >10 8.38  0.4 >10 >10 
131 >10 >10 >10 >10 
132 >10 >10 >10 >10 
 
5.3.2 Results for Cancer Preventive Activity 
Compounds 119–121, 123, 124, 126, 127, 129–132 were evaluated for in vitro EBV-EA 
inhibition, and the results are shown in Table 5.2. From the results, an-N-heptane acetamide group 
reduced the activity compared with a carboxylic acid (123 vs 120, 124 vs 121, 130 vs 129) at C-28. 
The four most potent analogs (120, 121, 126, and 129) all contained a C-28 carboxylic acid, and the 
most active compound 121, with a 3-carboxylic acid, 4,23-vinyl group, and 28-carboxylic acid, 
displayed 100%, 91.6%, 65.1%, and 26.6% inhibition at 1 × 10
3
 5 × 10
2
, 1 × 10
2
, 1 × 10 mol 
ratio/TPA, respectively, with an IC50 value of 295 mol ratio/TPA. Even at the low concentration (1 × 
10 mol ratio/TPA), 121 exhibited more inhibitory activity than curcurmin, a known cancer preventive 
agent. This result may because the prop-1-en-2-yl group at C-5 is similar to a prenyl group, which is 
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an effective modification in cancer prevention research. Compounds 120 and 121 with a carboxylic 
acid and methyl ester, respectively, at C-3showed similar potency. Regarding the C-4 
position,comparison of 120, 126, and 129 resulted in the general rank order of potency, 120 (C=CH2) 
> 126 (CH-CH2OH) > 129 (CH-CH2OAc). Overall, the main difference between the SAR for cancer 
prevention and anticancer activity was that a carboxylic acid was better than a methyl ester at C-3 for 
the former effect. Further in vivo study is ongoing. 
Table 5.2 EBV-EA Inhibition Ability of Newly Synthesized Betulinic Acid Derivatives.    
 
Percentage EBV-EA positive cells 
Compound concentration (mol ratio/TPA
a
) 
compd 1000 500 100 10 IC50
c
 
119 15.30.4 (60)b 61.41.4 83.22.1 1000.3 523 
120 0.00.5 (70) 29.11.5 66.92.5 94.20.4 311 
121 0.00.4 (70) 26.61.5 65.12.4 91.60.5 295 
123 7.10.6 (60) 54.41.6 77.22.5 1000.3 479 
124 6.70.5 (60) 50.21.5 76.32.4 1000.2 460 
126 0.00.4 (70) 31.61.3 68.12.3 96.30.4 323 
127 3.70.5 (70) 36.41.6 71.32.5 1000.4 386 
129 0.00.5 (70) 33.81.5 68.82.3 98.20.5 335 
130 7.80.6 (60) 56.01.6 79.42.3 1000.4 490 
131 6.60.5 (60) 52.11.4 77.52.5 1000.4 471 
132 11.30.4 (60) 57.21.6 81.32.3 1000.2 501 
BA 7.90.4 (60) 37.21.2 75.12.3 1000.6 403 
Bevirimat 6.10.3 (60) 36.11.3 74.22.2 96.50.9 396 
curcurmin 0.00.2 (60) 22.81.2 81.72.5 1000.5 341 
a 
TPA concentration is 32 pmol/mL. 
b 
Values in parentheses are viability percentages of Raji cells. 
c 
IC50 in mol/ratio TPA 
 
5.3.3 Results of Anti-HIV Activity 
All of the compounds were assayed for anti-HIV replication activity. All compounds, except for 
127, 128, 131, and 132, exhibited some cytotoxicity against MT-4 cells at 4 µg/ml, and thus, 
cytotoxic and anti-HIV activities could not be differentiated. Only the oxepanone ring A-analog 119 
retained some anti-HIV activity when the concentration was reduced below 4 µg/ml. However, it was 
less potent than bevirimat or A43-D, which has the same C-28 side chain as 119. Further mechanistic 
study is ongoing, and the anti-viral activity against a DSB-resistant strain will also be tested. 
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Although several literature articles have indicated that 3,4-seco compounds exhibited HIV protease 
inhibition, they did not report inhibition of viral replication data, implying that these compounds are 
unlikely to inhibit viral replication. Accordingly, while our newly synthesized compounds may have 
protease inhibition activity (not tested), they cannot inhibit viral replication, which diminishes their 
value for further protease inhibition study. 
Figure 5.1. Structure of A43-D. 
 
 
5.4 Conclusions 
In this study, 13 new BA derivatives were designed, synthesized, and evaluated for anticancer, 
cancer prevention, or anti-HIV activity. For cytotoxicity activity, compounds 120, 123, 126, and 129 
exhibited GI50 < 10 µM. Compound 120 with a 3-methyl ester, 4,23-vinyl group, and 28-carboxylic 
acid was the most potent. SAR study suggested a methyl ester at C-3, hydroxyl or acetate at C-23 
would reduce the activity compared with a double bond between C-4 and C-23, and a carboxylic acid 
was more effective than an N-heptane acetamide at C-28. Notably, compound 126 was more toxic to 
MDR KBvin than the parental KB cell line, indicating a potential chemosensitizing activity. Further 
chemosensitizing assays are in progress. In the cancer prevention assay, the SAR trends were similar 
to those found with anticancer activity, except that a free carboxylic acid was preferred at C-3. For 
anti-HIV activity, only compound 119 with an ε-lactone A ring and 28-N heptane acetamide showed 
weak activity, and its mechanism of action is under study. 
 
89 
 
5.5 Materials and Methods 
Chemistry 
General. 
1
H NMR (400 MHz) spectra were measured on a Varian Inova spectrometer with TMS as 
the internal standard. Mass spectra were measured on a Shimazu LCMS-IT-TOF. All reactions were 
monitored by thin-layer chromatography (TLC) on aluminum sheets (silica gel 60 F254 plate, 20 × 20, 
Merk). Melting points were recorded on a Fisher Johns melting apparatus without correction. 
Medium-pressure column chromatography was used in Grace Companion systems with silica 40 µM 
columns from Grace Inc. All final compounds are >95% pure, based on HPLC. Anhydrous solvents 
were purchased from commercial suppliers. 
General Procedure for Compounds 116 and 130 
A mixture of 114 or 129 and oxalyl chloride (10 mol eq.) was stirred at 0 
o
C for 30 min and then 
dried under vacuum. The residue was redissolved in anhydrous CH2Cl2 and added dropwise to a 
solution containing 1,7-diaminoheptane (3 mol eq.) in anhydrous CH2Cl2 at r.t..After stirring 
overnight, the mixture was washed with water and the organic layer was concentrated. The crude 
product was purified by flash chromatography on a silica gel column eluted with CH2Cl2/MeOH. The 
amine intermediate in anhydrous pyridine was added to acetic anhydride (2 mol eq.) and DMAP 
(catalytic amount) and stirred overnight at room temperature. The reaction mixture was added CH2Cl2 
and washed with 1N HCl and Sat. NaHCO3 solution. The organic layer was dried over Na2SO4, 
concentrated and purified by flash chromatography on a silica gel column eluted with CH2Cl2/MeOH 
to yield the corresponding product. 
Compound 116. Yield 55%; colorless amorphous; 
1
H NMR (CDCl3) δ 5.59-5.62 (2H, m, 2 × NH), 
3.05-3.65 (4H, m, 2 × NHCH2), 1.97 (3H, s, -NHCOCH3), 1.07, 1.02, 0.96, 0.95, 0.93 (each 3H, s, 4 × 
CH3), 0.85, 0.74 (each 3H, d, J = 6.8 Hz, H-29, 30); ESI-MS m/z: 611 [M+H]
+
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Compound 130. Yield 46%; colorless amorphous; 
1
H NMR (CDCl3) δ 5.68-5.62 (2H, m, 2 × NH), 
4.17 (1H, dd, J = 3.2, 10.8 Hz, H-23), 3.69 (1H, t-like, H-23), 3.67 (3H, s, OMe), 3.29-3.12 (4H, m, 2 
× NHCH2), 2.03 (3H, s, -OCOCH3), 1.97 (3H, s, -NHCOCH3), 0.99 (3H, d, J = 6.8 Hz, CH3), 0.93 
(6H, s, 2 × CH3), 0.86-0.84 (6H, 2 × CH3), 0.74 (3H, d, J = 6.8 Hz, CH3); ESI-MS m/z: 702 [M+H]
+
 
General Procedure for Compounds 117, 118 and 119 
3-Chloroperoxybenzoic acid (77%, 5-10 mol eq.) was added to the flask containing compounds 
114, 115, or 116 in CHCl3 and the mixture was stirred overnight at room temperature. NaHCO3 (aq.) 
solution was added to stop the reaction. The solution was partitioned three times with CH2Cl2, dried 
over Na2SO4, and concentrated. The crude product was purified by flash chromatography on a silica 
gel column eluted with hexane/EtOAc. 
Compound 118. Yield 42%; colorless amorphous; 
1
H NMR (CDCl3) δ 7.36-7.30 (5H, m. aromatic 
H), 5.13, 5.07 (2H, d, J = 12.4 Hz, benzylic H), 2.58-2.64 (1H, m, H-2), 2.45-2.51 (1H, m, H-2), 1.46, 
1.38 (each 3H, s, H-23, 24), 1.04, 0.91. 0.78 (each 3H, s, 3 × CH3), 0.84, 0.74 (each 3H, d, J = 6.8 Hz, 
H-29, 30); ESI-MS m/z: 563 [M+H]
+
 
Compound 119. Yield 52%; colorless amorphous ; 
1
H NMR (CDCl3) δ 5.58 (1H, t-like, -NH), 5.52 
(1H, bs, -NH), 3.33-3.13 (4H, m, 2 × NHCH2), 1.97 (3H, s, -NHCOCH3), 1.46, 1.39 (each 3H, s, H-
23,24), 1.06, 0.98, 0.94 (each 3H, s, 3 × CH3), 0.85, 0.74 (each 3H, d, J = 6.8 Hz, H-29, 30); ESI-MS 
m/z: 627 [M+H]
+
 
General Procedure for Compounds 120, 122 and 123 
To a solution containing 117, 118, or 119 in methanol, several drop of conc. H2SO4 was added. 
The solution was stirred overnight and only one spot was obtained. Methanol was evaporated and the 
crude product was purified by flash chromatography on a silica gel column eluted with hexane/EtOAc 
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Compound 120. Yield 55%; colorless amorphous; 
1
H NMR (CDCl3) δ 4.84, 4.64 (each 1H, s, H-23), 
3.65 (3H, s, OMe), 1.71 (3H, s, H-24), 0.97 (6H, s, 2 × CH3), 0.85 (3H, d, J = 6.8 Hz, CH3), 0.83 (3H, 
s, CH3), 0.76 (3H, d, J = 6.8 Hz, CH3); ESI-MS m/z: 485 [M-H]
-
 
Compound 122. Yield 80%; colorless amorphous; 
1
H NMR (CDCl3) δ 7.36-7.32 (5H, m, CH2C6H5), 
4.84 (1H, s, H-23), 4.63 (1H, s, H-23), 3.65 (3H, s, OMe), 1.71 (3H, s, H-24), 0.93 (3H, s, CH3), 0.84 
(3H, d, J = 6.8 Hz, CH3), 0.80, 0.78 (each 3H, s, 2 × CH3 ), 0.74 (3H, d, J = 6.8 Hz, CH3) 
Compound 123. Yield 62%; colorless amorphous ; 
1
H NMR (CDCl3) δ 5.58 (1H, t-like, -NH), 5.52 
(1H, bs, -NH), 4.84 (1H, s, H-23), 4.64 (1H, s, H-23), 3.65 (3H, s, -OMe), 3.29-3.13 (4H, m, 2 × 
NHCH2), 1.97 (3H, s, -NHCOCH3), 1.72 (3H, s, H-24), 0.97, 0.96, 0.83 (each 3H, s, 3 × CH3), 0.85, 
0.74 (each 3H, d, J = 6.8 Hz, H-29, 30); ESI-MS m/z: 641 [M+H]
+
 
Synthesis of Compound 125 
To a solution of 120 (1.4 g, 2.4 mmol) in anhydrous THF (20 ml) at 0 
o
C under argon, 2M of 
BH3SMe2 solution was added (6 ml, 12 mmol). After starting material disappeared, NaOH solution 
[1200 mg in EtOH/H2O (65:35)] was added at 0 
o
C, and then H2O2 solution was added (30%wt, 1.5 
ml). After one hour, water was added, the mixture was extracted three times with EtOAc, and the 
organic layer was dried over Na2SO4. The crude product was purified by Grace flash chromatography 
using silica gel column eluted with hexane/EtOAc.  
Compound 125. Yield 61%; colorless amorphous ; 
1
H NMR (CDCl3) δ 3.76 (1H, dd, J = 3.2, 10.4 
Hz, H-23), 3.66 (3H, s, OMe), 3.26 (1H, t-like, H-23), 1.02 (3H, d, J = 6.8 Hz, CH3), 0.91 (3H, s, 
CH3), 0.84 (3H, d, J = 6.8 Hz, CH3), 0.74-0.73 (6H, 2 × CH3); ESI-MS m/z: 595 [M+H]
+
 
General Procedure for De-protection of Benzylic Group 
Compound 125 was dissolved in CH2Cl2/MeOH solution (minimal amount of CH2Cl2) and excess 
Pd/C was added. Pressurized hygrogen was applied for one hour. Pd/C was filtered and solvent was 
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evaporated. The crude product was purified by Grace flash chromatography using silica gel column 
eluted with hexane/EtOAc. 
Compound 126. Yield 72%; colorless amorphous; 
1
H NMR (CDCl3) δ 3.76 (1H, dd, J = 2.4, 10 Hz, 
H-23), 3.67 (3H, s, OMe), 3.25 (1H, t, J = 9.6 Hz, H-23), 1.03 (3H, d, J = 6.8 Hz, CH3), 0.94, 0.92 
(each 3H, s, 2 × CH3 ), 0.86-0.84 (6H, 2 × CH3), 0.75 (3H, d, J = 6.8 Hz, CH3); ESI-MS m/z: 503 [M-
H]
-
 
General Procedure for Compounds 127, 128 and 132 
A mixture of 125 or 131, 2,2-dimethylsuccinic anhydride (for 127, 132) or glutaric anhydride (for 
128) (5 mol eq.), and DMAP (1 mol eq.) in anhydrous pyridine was refluxed overnight. The mixture 
was concentrated to remove pyridine, 1N HCl solution was added, and the solutions extracted with 
EtOAc. The crude product was purified by Grace flash chromatography using silica gel column eluted 
with hexane/EtOAc (for 127, 128) or CH2Cl2/MeOH (for 132) with minor amount of the dimethyl 
positional isomers for 127 and 132.  Compounds 127 and 128 were obtained following the de-
protection procedure described above. 
Compound 127. Yield 57%; colorless oil; 
1
H NMR (CDCl3) δ 4.30 (1H, dd, J = 2.8, 8 Hz, H-23), 
3.67 (3H, s, OMe), 3.61 (1H, t-like, J = 11.2, 10.4 Hz, H-23), 2.59 (2H, s, -CH2COOCH2), 1.30, 1.27 
(each 3H, s, -C(CH3)-COOH), 0.99 (3H, d, J = 6.8 Hz, CH3), 0.94, 0.92 (each 3H, s, CH3), 0.84 (3H, 
d, J = 7.2 Hz, CH3), 0.74 (3H, d, J = 6.8 Hz, CH3); ESI-MS m/z: 631 [M-H]
-
 
Compound 128. Yield 17%; colorless oil; 
1
H NMR (CDCl3) δ 4.18 (1H, dd, J = 3.2, 10.8 Hz, H-23), 
3.69 (1H, t-like, H-23), 3.64 (3H, s, OMe), 2.40-2.34 (4H, m, 2 × OCOCH2CH2), 0.96 (3H, d, J = 6.4 
Hz, CH3), 0.918, 0.911 (6H, s, 2 × CH3), 0.85 (3H, s, CH3), 0.82 (3H, d, J = 7.2 Hz, CH3), 0.72 (3H, d, 
J = 6.4 Hz, CH3); ESI-MS m/z: 617 [M-H]
-
 
Compound 132. Yield 35%; colorless oil; 
1
H NMR (CDCl3) δ 5.62-5.55 (2H, m, 2 × NH), 4.28 (1H, 
dd, J = 2.8, 7.6 Hz, H-23), 3.61 (1H, t-like, J = 10.4 Hz, H-23), 3.31-3.13 (4H, m, 2 × NHCH2 ), 2.66, 
2.65 (1H, s, -CH2COOCH2), 1.98 (3H, s, -NHCOCH3), 1.29, 1.27 (each 3H, s, -C(CH3)-COOH), 0.96 
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(3H, d, J = 6.8 Hz, CH3), 0.94, 0.92 (3H, s, 2 × CH3), 0.87-0.84 (6H, m, 2 × CH3), 0.74 (3H, d, J = 6.8 
Hz, CH3); ESI-MS m/z: 772 [M-H]
-
 
Synthesis of Compound 129 
A mixture of 126, acetic anhydride (2 mol eq.), and DMAP (1 mol eq.) in anhydrous pyridine was 
stirred overnight at room temperature. The mixture was concentrated to remove pyridine, 1N HCl 
added, and the solution was extracted with EtOAc. The crude product was purified by Grace flash 
chromatography using silica gel column eluted with hexane/EtOAc. Compound 129 was obtained 
following the de-protection procedure mentioned above. 
Compound 129. Yield 85%; colorless amorphous; 
1
H NMR (CDCl3) δ 4.18 (1H, dd, J = 3.6, 10.4 Hz, 
H-23), 3.68 (1H, t-like, H-23), 3.67 (3H, s, OMe), 2.03 (3H, s, OCOCH3), 0.99 (3H, d, J = 6.8 Hz), 
0.94, 0.93 (each 3H, s, 2× CH3), 0.87-0.84 (6H, 2× CH3), 0.75 (3H, d, J = 6.8 Hz); ESI-MS m/z: 545 
[M-H]
-
 
General Procedure for Compounds 121, 124 and 131 
Compounds 120, 123 or 130 was stirred in 4N NaOH THF solution for overnight. EtOAc was added 
and the solution was washed with water and 1N HCl solution. The organic layer was dried over 
Na2SO4 and the crude product was purified by flash chromatography on a silica gel column eluted 
with CH2Cl2/MeOH. 
Compound 121. Yield 82%; colorless amorphous; 
1
H NMR (CDCl3) δ 4.85, 4.65 (each 1H, s, H-23), 
1.72 (3H, s, H-24), 0.98, 0.97 (each 3H, s, CH3), 0.86-0.84 (6H, 2 × CH3), 0.76 (3H, d, J = 6.8 Hz, 
CH3); ESI-MS m/z: 471 [M-H]
-
 
Compound 124. Yield 51%; colorless amorphous; 
1
H NMR (CDCl3) δ 5.58 (1H, t-like, NH), 5.51 
(1H, bs, NH), 4.84 (1H, s, H-23), 4.65 (1H, s, H-23), 3.29-3.13 (4H, m, 2 × NHCH2), 1.97 (3H, s, 
NHCOCH3), 1.72 (3H, s, CH3), 0.97, 0.96 (3H, s, 2 × CH3), 0.85 (3H, d, J = 6.8 Hz, CH3), 0.84 (3H, s, 
CH3 ), 0.75 (3H, d, J = 6.8 Hz, CH3); ESI-MS m/z: 625 [M-H]
-
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Compound 131. Yield 58%; colorless amorphous; 
1
H NMR (CDCl3) δ 5.59-5.54 (2H, 2 × NH), 3.77 
(1H, dd, J = 3.2, 10.4 Hz, H-23), 3.31-3.11 (5H, m, 2 × NHCH2 and H-23), 1.97 (3H, s, NHCOCH3), 
1.03 (3H, d, J = 6.8 Hz, CH3), 0.94-0.93 (6H, 2 × CH3), 0.86-0.84 (6H, 2 × CH3), 0.74 (3H, d, J = 6.8 
Hz, CH3); ESI-MS m/z: 643 [M-H]
-
 
Anti-HIV Assay 
An anti-HIV-1 infectivity assay previously reported was used in the experiments. A 96-well 
microtiter plate was used to set up the HIV-1 NL4-3 replication assay. HIV-1 NL4-3 at a multiplicity 
of infection (MOI) of 0.01 was used to infect MT4 cells. Culture supernatants were collected on day 4 
post infection for the p24 assay using an ELISA kit from ZeptoMetrix Corporation (Buffalo, New 
York). 
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Chapter 6  
Concluding Remarks and Perspectives for Future Directions of Research 
on DDB and BA Derivatives 
 
6.1 DDB as a Promising Lead for Cancer Prevention and Chemosensitization 
6.1.1 SAR Conclusions on DDB Analogs as Leads for Chemosensitization and Cancer 
Prevention  
DDB, a clinically used hepatoprotectant, served as a lead to further design and synthesize new 
analogs for chemosensitizing and chemopreventive activities.    
Thirty-three DDB analogs were newly synthesized and evaluated for chemoreversal action in 
comparison with the parent compound, DDB. Reduced activity was seen for compounds containing a 
3-position halogen, such as bromide or iodide, while increased activity was seen for compounds 
bearing a 2,2-position methyl ester side chain, such as pivalate, 2-methylbutanoate, cyclic aliphatic, 
and trimethoxyphenyl. Among all tested compounds, DDB derivatives 83 and 90 were 5–10 times 
more effective than VRP for TAX and VCR reversal ability. Analog 73 with a pivalate side chain also 
showed five-fold greater chemosensitizing effect than VRP for DOX.  
Nineteen DDB analogs with 2,2′-bismethyl ester and ether substituents were designed and 
synthesized for chemopreventive activity. All analogs showed potent EBV-EA inhibition in vitro and 
significant inhibition of the EBV-EA activation was seen for analogs 82-85, 104, 106, and 107, with 
unsaturated side chains or terminal carboxylic acids. Remarkably, the highest inhibitory effects 
(100%, 78.4%, 49.7% and 10.9% inhibition at 1 × 10
3
, 5 × 10
2
, 1 × 10
2
, 1 × 10 mol ratio/TPA, 
respectively) were seen with prenyl derivative 106, which were greater than those of curcumin at the 
low concentrations. In an in vivo assay, DDB analogs 83, 85, and 106 significantly delayed the
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formation of mouse skin papillomas and reduced the number of papillomas after initiation and 
promotion by a cancer promoting substance, TPA. 
Importantly, all active DDB analogs displayed no cytotoxicity as chemosensitizers or anti-tumor 
promoters, suggesting that they have potential for long term use for further clinical development as 
chemosensitizing or chemopreventive agents.  
 
6.1.2 Design, Synthesis of DDB Analogs as Novel Chemosensitizers 
Based on the SAR study, 2,2-methylene ester DDB analogs were effective for 
chemosensitization of certain anticancer drugs.  Therefore, additional 2,2-methylene ester DDB 
analogs are proposed to extend the current SAR. To quickly assess the effect of each direction of 
modification, the proposed analogs can be readily prepared using commercially available materials 
via the synthetic scheme shown below in Scheme 6.1. Compounds 133 and 134 are proposed in order 
to compare the effects of chain length and hydrophobicity compared with previously synthesized 
compounds 71, 72, 74, and 75. Compound 135 is proposed to evaluate the combined effects of a 
prenyl side chain and cyclohexane ring. Hydrophobicity is critical in designing P-gp inhibitors, and 
Clog P values from 4.8–6.5 are considered to be important. However, a wide spectrum of 
hydrophobicity should be studied to establish a clear cut off of suitable hydrophobicity. Accordingly, 
compounds 136 and 137 contain very bulky and hydrophobic ring systems. The design of compounds 
138 and 139 is based on the chemosensitizing modification of dicamphanoyl-dihydropyranochrome 
(DCP) and dicamphanoyl-dihydropyranoxanthone (DCX) compounds (unpublished data). 
Commercially available camphanic and (1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-carbonyl 
groups are proposed. Nitrogen is a bioisostere substituent of the oxygen atom, so the simple and 
commercially available 4-(dimethylamino)benzoyl group in 140 should provide a rational comparison 
with compounds 87 and 88 for SAR study. Compounds 141–146 are designed based on a 
modification study of 3R,4R-disubstituted-2,2-dimethyldihydropyrano[2,3-f]chromone (DSP).1 In 
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the study, an (E)-3-(4-methoxyphenyl)acryloyl substituent led to good activity, but di- and tri-
methoxy substituents were not included. As found in Chapter 3, a DDB analog with trimethoxy 
substitution (90) showed quite potent activity. Therefore, mono-, di-, tri-methoxy substituents are 
proposed. 
 
Scheme 6.1. Proposed Synthetic Pathway and Substitutions of 2,2-Methylene Ester DDB 
Analogs. 
 
 
As mentioned above, nitrogen often serves as a bioisostere for oxygen in drug design.
2
 In addition, 
an amide linkage was effective in previous chemosensitizing research.
3
 Thus, 2,2-bis-methylene 
amide DDB analogs (in order to avoid stereochemistry issues) are proposed, and the synthetic 
pathway is also shown below (Scheme 6.2). 2,2-Bishydroxymethyl biphenyl will be used as the 
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starting material. A Ritter reaction will be applied to avoid hazardous and explosive azide reagents 
(ex. NaN3).
4, 5
 Carbenium ion formation followed by electrophilic addition of chloroacetonitrile will 
lead to 147. Subsequent cleavage of the chloroacetyl group with thiourea and heating will give the 
desired compound 148. Various acyl chlorides, including previous active substitutions, can be used to 
prepare various analogs, which will be tested for chemosensitizing activity to compare the effect of 
ester and amide. 
 
Scheme 6.2. Proposed Synthetic Pathway to 2,2-Methylene amide DDB Analogs. 
 
 
6.1.3 Design and Synthesis of DDB Analogs as Novel Chemopreventive Agents 
From the conclusions of Chapter 4, 2,2-methylene ester DDB analogs are effective for 
chemopreventive activity, especially with the presence of an unsaturated side chain or terminal 
carboxylic acid. Based on this information, several 2,2-methylene ester analogs have been designed 
(Scheme 6.3) and will be prepared by the same synthetic pathway described in Chapter 4. Although 
DDB analogs with a terminal carboxylic acid have been effective (see compounds 85 and 104), the 
SAR has not been fully explored. Therefore, the acids selected will have different lengths or 
branching (149–153) or contain more rigid (154–158) or aromatic (159–160) systems, as well as be 
commercially available. The branched substituents in 151, 152, and 153 were also used in betulinic 
acid modification studies. Bulky and rigid acids (154 and 155) are proposed to study the effect of 
steric hindrance. Compounds 156–158 are proposed to evaluate the combined effect of an acid and 
unsaturated group, especially the presence of a carboxylic acid in a prenyl group (158). Two benzoate 
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substituents (159–160) were selected to compare the effect of insertion of an aromatic group. Analogs 
with an ether linkage will also be designed based on the results of corresponding ester linked 
compounds (see compounds 83 and 106). In addition, amide analogs, again based on bioisostere 
design, can be prepared by the synthetic pathway shown above. 
 
Scheme 6.3. Proposed DDB Analogs and Synthetic Pathway for Cancer Prevention. 
 
 
6.2 A-ring Modification of Betulinic Acid Derivatives 
6.2.1 SAR Conclusions with A-ring Opened Betulinic Acid Derivatives 
Thirteen new 3,4-seco BA derivatives were designed, synthesized, and evaluated for cancer 
prevention, anticancer, and anti-HIV activity. In the cancer prevention study, analogs with a terminal 
(C-28) carboxylic acid, such as 120, 121, 126, and 129, significantly inhibited EBV-EA activation, 
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showing 100.0% inhibition at the highest tested concentration. The most active compound 121 with a 
3-carboxylic acid and 4,23-vinyl group displayed 100% inhibition at 1 × 10
3
 mol ratio/TPA, and 
91.6%, 65.1% and 26.6% inhibition at 5 × 10
2
, 1 × 10
2
, 1 × 10 mol ratio/TPA, respectively, with an 
IC50 value of 295 mol ratio/TPA, more potent than the known cancer preventive agent curcumin. In 
the cytotoxicity assays in A549, DU-145, K562 and KB cell lines, compounds 119, 120, 123, 126, 
and 129 exhibited GI50 < 10 µM. Compound 120 with a 3-methyl ester and 4,23-vinyl group was the 
most potent. Hydration of the 4,23 double bond to form a hydroxymethylene and subsequent 
esterification with acetic, 3,3-dimethylsuccinic, or glutarie acid reduced activity. A C-28 carboxylic 
acid analog was more potent than the corresponding C-28 N-heptane acetamide. The 
chemosensitizing effects of the compounds at non-toxic concentrations are under investigation. 
Regarding anti-HIV activity, most of the compounds were toxic to MT-4 cells. However, compound 
119 with an ε-lactone A-ring and 28-N-heptane acetamide showed activity and its mechanism of 
action is under study. A long side chain on C-28 and retained A-ring seem to be crucial for anti-HIV 
activity.  
 
6.2.2 Future Research Directions with A ring Opened Betulinic Acid Derivatives 
From the cancer prevention results in Chapter 5, A-ring opened BA analogs with a C-4,23 vinyl 
group were better than analogs with hydroxymethylene or acetoxymethylene groups, and a carboxylic 
acid was better than its methyl ester at C-3. In addition, SAR in Chapter 4 suggested that short fatty 
acid and acidic side chains were effective in DDB compounds. Based on these results, A-ring opened 
BA analogs will be prepared by the synthetic scheme shown in Scheme 6.4. The terminal methyl ester 
in starting material 120 can be selectively reduced to a hydroxymethylene group (121) without 
altering the C-28 carboxylic acid. The allyl group in 122 can be produced by treating 121 with 
trifluoromethanesulfonic anhydride (Tf2O) followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). 
The effects of the polarity and water solubility of the three compounds can then be compared. The 
hydroxy group found in A-ring opened 121 can be seen as analogous to the C-3 hydroxyl found in 
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betulinic acid (BA). Thus, it will be esterified with the active side chains found in Chapter 4 to assess 
whether the corresponding A-ring opened analogs will exhibit cancer preventive activity.  
 
Scheme 6.4. Proposed A-ring Opened BA Derivatives for Cancer Prevention. 
 
 
Based on previous BA cytotoxicity results, several analogs are proposed and their synthetic 
scheme is shown below (Scheme 6.5). The main goal is to explore esters with different chain lengths 
or branching to establish complete SAR at the C-3 position. The oxepanone ring-A starting material 
can be produced from 3-oxo-BA using mCPBA. Different alcohols, such as ethanol and propanol, can 
be used as solvents as well as reagents to form esters with different chain lengths at C-3.   
Scheme 6.5. Proposed New BA Derivatives for Cytotoxicity. 
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According to the SAR analysis in Chapter 5, a long chain on C-28 is essential for anti-HIV 
activity. Anti-entry assays are now ongoing, as prior BA derivatives with long chains at C-28 usually 
exhibited anti-entry activity. Further synthetic modifications are proposed, while the mechanism is 
being confirmed. Different chain lengths and different linkages will be incorporated through the 
synthetic pathway shown below (Scheme 6.6). Two, five, and ten carbon linking (R) groups are 
designed to optimize suitable chain length. As oxygen and nitrogen are bioisosteres, ester linked 
compounds with different chain lengths are also designed. In the synthetic scheme, the 3-oxo-28-
carboxylic acid is used as starting material. The C-28 side chains can easily be introduced by acyl 
chloride formation, nucleophilic attack of amine or alcohol, and acetylation with acetic anhydride. 
Desired products with the expanded A-ring lactone can be achieved via a Baeyer-Villiger reaction 
using mCPBA. 
 
Scheme 6.6. Proposed New BA Derivatives for Anti-HIV Activity and Their Synthetic Scheme. 
 
 
6.2.3 Successful Six Member Ring BA Derivatives 
6.2.3.1 Introduction 
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The main target of the BA derivative bevirimat is the HIV maturation step. Inhibition of this step 
blocks the cleavage of precursor Gag protein to functional p24, resulting in non-infectious virus. 
However, the crystal structure of Gag protein is still unavailable, and the actual binding site of 
bevirimat is still unknown. Therefore, in order to explore new BA analogs for anti-maturation activity, 
ligand-based drug design will be applied. 
Common strategies for analog design are 1) bioisosteric replacement, 2) rigid analogs, 3) 
homologation of alkyl chain or alteration of chain branching, changes in ring size, and ring position 
isomers, 4) stereoisomers and geometric isomers, 5) fragment of a lead molecule, and 6) alteration in 
interatomic distance.
2
 The advantage of making rigid analogs is to reduce three-dimensional 
movement of a side chain or to investigate the effect of freedom of a side chain. Based on this logic, 
the BA analog 123 was designed (Figure 6.1). 
 
Figure 6.1. Proposed Rigid BA Analog. 
 
 
Addition of a sixth ring (F-ring) joined to the A-ring will reduce the freedom of the prior DSB 
side chain. A recent example of successful ring construction in antiviral research convinced us of the 
validity of this approach. N-4-Hydroxy pyrimidine nucleosides are a recent novel class of anti-herpes 
agent. Two bicyclic derivatives (124 and 125) of ddC, a NRTI targeting HIV reverse transcriptase, 
are shown in Figure 6.2. These two compounds inhibited cultural herpes simplex (HSV) and varicella 
zoster virus (VZV) and had similar inhibitory potency toward VZV replication on VZV nuclease 
kinase with a 40-fold selectivity.
6
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Figure 6.2 N-4-Hydroxy Pyrimidine Nucleoside and Related Bicyclic Analogs 
 
 
6.3.2.2 Synthesis of the Six-Ring BA Derivative 
Robinson annulation, which is Michael addition followed by ring cyclization, can be applied to 
construct the F-ring of a new BA derivative. Michael addition without an activator (Mukaiyama 
Michael reaction) was tried several times, but resulted in low yields with mostly starting material 
recovered and two isomers obtained. Therefore, a Michael addition with a nitrile group (β-keto nitrile) 
as an activator was applied. The β-keto nitrile group in 128 can be introduced by two methods (Figure 
6.3). The conventional method is a three-step process: 1) hydroxymethylene ketone formation (126) 
using sodium hydride and ethyl formate, 2) isoxazole formation (127) using hydroxylamine 
hydrochloride and sodium acetate, and 3) β-keto nitrile group formation (128) using sodium 
methoxide. Low yields (20-40 %) were obtained and the three steps took three days to complete. An 
easier synthetic pathway to the β-keto nitrile (128) was found by nucleophilic attack of the enolate of 
115, formed with lithium diisopropylamide (LDA), on p-toluenesulfonyl cyanide (p-TsCN), which 
led to relative high yields (60-80 %) of 128 within a short time period (one hour).  
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Figure 6.3. Two Synthetic Methods for Forming β-Keto Nitrile BA Derivative (128). 
 
 
Michael addition on the β-keto nitrile BA (128) was achieved using methyl vinyl ketone (MVK) 
and triethylamine (Scheme 6.7). Only one product (129) was obtained in high yield. The product’s 
stereochemistry is explained in Figure 6.4. The axial C-24 methyl group would disfavor an approach 
on MVK from the β-direction (and BA cannot easily flip into another configuration due to its 
pentacyclic structure). Therefore, the attack would come from the α-direction, and the nitrile group 
would end up in the β-position.7  
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Scheme 6.7 Synthetic Scheme for the F-ring BA Derivative. 
 
Figure 6.4. Explanation of Stereochemistry of C-2 Nitrile Group of 129. 
 
 
Cyclization of the Michael addition product (129) was needed to complete the Robison 
annulation. Several basic conditions (Table 6.1) have been reported in the literature and were 
attempted here to obtain cyclic products. However, because of the huge steric effect on the A-ring, 
retro Michael reaction took place predominately to return to the starting cyano ketone (128). Only a 
small amount of cyclic product (130) was obtained with a bulky base or moderate basicity at low 
temperature (ex. 0.022 M NaOMe at 0 
o
C). Finally, a Mukaiyama aldol condensation [formation of 
the trimethylsilylenol ether of the C-3 ketone followed by cyclization with the Lewis acid titanium 
tetrachloride (TiCl4)] was more effective and raised the yield of 130 up to 40–50%.
8
 However, 
dehydration of the β-hydroxyketone was not achieved using trifluoroacetic anhydride and 
triethylamine. Other dehydration conditions will be needed to complete the synthesis of 131. 
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Table 6.1. Basic Cyclization Conditions. 
Base Solvent Temperature Time 
128 
(Retro Michael 
product) 
130 
0.022 M 
NaOMe 
THF/MeOH 
(8:1) 
0 C 15 min major < 2% 
0.022 M 
NaOMe 
THF/MeOH 
(8:1) 
0 C 30 min major < 1% 
0.022 M 
NaOMe 
THF/MeOH 
(8:1) 
r.t. overnight major 0 
0.6 mmol 
NaOMe 
Toluene r.t. 
30 min or 
overnight 
major 
0 
(Unknown 
product appeared 
with double bond 
signal in NMR ) 
0.8 equiv. 
LDA
a
 
THF -78 C 30 min major < 5 % 
4N 
NaOH 
THF/MeOH r.t. 
30 min or 
overnight 
major 0 
1M 
tBuOK 
THF/MeOH r.t. 
30 min or 
overnight 
major 0 
1.1 eq. 
KHMDS
b
 
THF -78  C 30 min major < 5% 
a.
LDA: lithium diisopropylamide, 
b.
 KHMDS: Potassium bis(trimethylsilyl)amide 
 
6.2.4 Future Research Direction of F-ring BA Derivative Modification 
6.2.4.1 Optimize Cyclization Condition and Complete Dehydration of β-Hydroxyketone 
Since TiCl4 (a Lewis acid) worked for the cyclization to form β-hydroxyketone (130), a series of 
Lewis acids such as BF3, SnCl4, and ZrCl4 will be used to optimize the cyclization step. Another 
rational method is Knoevenagel condensation using pyrrolidine with pH adjusted by acetic acid.
9
 
 
6.2.4.2 New F-ring BA derivatives 
Based on previous rigid analog design, several new F-ring BA derivatives are proposed and their 
synthetic pathway is shown below (Scheme 6.8). Newly synthesized BA derivative 131 will serve as 
a starting material. Exposure to potassium and hexamethyl phosphoric triamide (KHMD) will 
eliminate the nitrile group at C-2 as well as the C-28 benzyl group.
10
 1,4-Reduction by sodium 
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borohydride should give mainly β-hydroxylation at C-33 (133). Etherification with various protected 
ω-bromoacids (e.g., benzyl 2-bromoacetate and 3-bromopropanoate) followed by deprotection of the 
benzylic group by hydrogenation will give the desired compounds (135). 
 
Scheme 6.8. Proposed New F-ring BA Derivatives and Their Synthetic Route. 
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